Clinical Trial Collaboration and Supply Agreement by and among MSD International GmbH, MSD International Business GmbH, and Collaborator (as defined below)

Exhibit 10.8

EXECUTION VERSION

Clinical Trial Collaboration and Supply Agreement

by and among

MSD International GmbH,

MSD International Business GmbH,

and

Collaborator (as defined below)

*Certain exhibits and the schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon its request, however the registrant may request confidential treatment of omitted items.

Clinical Trial Collaboration and Supply Agreement - Information Sheet

MSD Agreement Number (LKR Number)	199305
Collaborator Entity Name	AUM Biosciences Pte. Ltd
Collaborator Address	▇▇ ▇▇▇▇▇ ▇▇., #▇▇-▇▇▇/▇, ▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
Collaborator Class Compound	MNK1/2 inhibitors
Collaborator Compound	AUM001
Collaborator Clinical Trial	The Phase 2 clinical trial described in the Protocol to evaluate AUM001 in combination with pembrolizumab vs. in combination with standard of care agent in patients with metastatic colorectal cancer.
Collaborator JDC Escalation Person Title	▇▇▇▇ ▇▇▇▇▇▇, Ph. D. Chief Operating Officer
Collaborator Notice Block	▇▇▇▇▇▇ ▇▇▇▇▇, CEO AUM Biosciences Pte. Ltd ▇▇ ▇▇▇▇▇ ▇▇▇▇, #▇▇-▇▇ ▇/▇, ▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
Effective Date	January 4, 2022
Safety Gate (Yes/No)	Yes

CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT

This Clinical Trial Collaboration and Supply Agreement is entered into as of the Effective Date, by and among MSD International GmbH (“MSDIG”), MSD International Business GmbH (“MSDIB” and, collectively with MSDIG, “MSD”), each having a place of business at ▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇, ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇, and Collaborator (as defined below), having a place of business at the Collaborator Address (as defined below). MSD and Collaborator are each referred to herein individually as a “Party” and collectively as the “Parties”.

RECITALS

MSD holds intellectual property rights to the MSD Compound (as defined below) and is developing the MSD Compound for the treatment of certain tumor types.

Collaborator is developing the Collaborator Compound (as defined below) for the treatment of certain tumor types.

Collaborator desires to sponsor the Collaborator Clinical Trial (as defined below) in which the Collaborator Compound and the MSD Compound would be dosed in Combination (as defined below).

MSD and Collaborator, consistent with the terms of this Agreement, desire to collaborate as described herein, including by providing the MSD Compound and the Collaborator Compound for the MSD Compound Study (as defined below).

NOW, THEREFORE, in consideration of the following mutual promises, covenants and conditions, the Parties, intending to be legally bound, agree as follows:

DEFINITIONS.

For all purposes of this Agreement, the capitalized terms defined in this Article 1 and throughout this Agreement shall have the meanings herein specified.

1.1.

“Affiliate” means, with respect to either Party, a firm, corporation or other entity that, now or hereafter, directly or indirectly owns or controls said Party, or, now or hereafter, is owned or controlled by said Party, or is under common ownership or control with said Party for so long as such control exists. The word “control” as used in this definition means: (i) the direct or indirect ownership of fifty percent (50%) or more of the outstanding voting securities of a legal entity; or (ii) possession, directly or indirectly, of the power to direct the management or policies of a legal entity through the ownership of voting securities, contract rights, voting rights, corporate governance or otherwise.

1.2.

“Agreement” means this agreement.

1.3.

“Alliance Manager” means the alliance managers appointed by the Parties in accordance with Section 2.3 (Joint Development Committee; Managers).

1.4.

“Applicable Law” means all federal, state, local, national and regional statutes, laws, rules, regulations and directives applicable to a particular activity hereunder, including performance of clinical trials, medical treatment and the processing and protection of personal and medical data, that may be in effect from time to time, including: (i) those promulgated by any Regulatory Authority; (ii) cGMP and GCP; (iii) Data Protection Law; (iv) export control and economic sanctions regulations that prohibit the shipment of United States-origin products and technology to certain restricted countries, entities and individuals; (v) anti-bribery and anti-corruption laws pertaining to interactions with government agents, officials and representatives; (vi) laws and regulations governing payments to healthcare providers; (vii) the listing or other rules or regulations of any stock exchange; and (viii) health, safety and environmental protections.

1.5.

“Business Day” means any day other than a Saturday, Sunday, or a day on which commercial banks located in the country (or, if in the United States, in the state) where the applicable obligations are to be performed are authorized or required by law to be closed.

1.6.

“cGMP” means the Good Manufacturing Practices officially published and interpreted by EMA, FDA and other applicable Regulatory Authorities as applicable to the Manufacture of the Compounds.

1.7.

“Change of Control” means: (a) the sale of all or substantially all of such Collaborator’s assets or business relating to the Collaborator Compound; or (b) a merger, reorganization or consolidation involving Collaborator in which the voting securities immediately prior thereto cease to represent at least fifty percent (50%) of the combined voting power of the surviving entity immediately after such merger, reorganization or consolidation; or (c) any Third Party (or group of Third Parties acting in concert) becoming the beneficial owner directly or indirectly, of fifty percent (50%) or more of the total voting power of Collaborator.

1.8.

“Clinical Quality Agreement” means an agreement to be entered into by the Parties pursuant to Section 2.4 (Clinical Quality Agreement) to address and govern the quality and handling of clinical drug to be supplied by the Parties for use in the MSD Compound Study.

1.9.

“Clinical Data” means Collaborator Clinical Data, Joint Clinical Data and MSD Clinical Data.

1.10.

“Clinical Safety Data” means all safety and tolerability data from the portions of the Collaborator Clinical Trial that do not contain the MSD Compound or other clinical trials involving the Collaborator Compound, including all safety reports containing information on adverse events, SAEs, and other information required by any FDA-reporting requirements, including summary tables of laboratory and radiographic data..

1.11.

“CMC” means “Chemistry Manufacturing and Controls” as such term of art is used in the pharmaceutical industry.

1.12.

“Collaborator” means the entity specified in the “Collaborator Entity Name” row of the Information Sheet.

1.13.

“Collaborator Address” means the address set forth for Collaborator in the “Collaborator Address” row of the Information Sheet.

1.14.

“Collaborator Background Patents” means any Patent Controlled by Collaborator or its Affiliate that claims or covers the Combination and is not a Joint Patent.

1.15.

“Collaborator Class Compound” means the class of compounds set forth in the “Collaborator Class Compound” row of the Information Sheet.

1.16.

“Collaborator Clinical Data” means all data (including raw data) and results generated by or on behalf of either Party or at either Party’s direction, or by or on behalf of the Parties together or at their direction, in the course of the Collaborator Compound Arm(s), if any Collaborator Compound Arm(s) are included in the Collaborator Clinical Trial. Collaborator Clinical Data does not include Sample Testing Results, Joint Clinical Data or MSD Clinical Data.

1.17.

“Collaborator Clinical Trial” means the clinical trial set forth in the “Collaborator Clinical Trial” row of the Information Sheet.

1.18.

“Collaborator Compound” means the compound set forth in the “Collaborator Compound” row of the Information Sheet, excluding, however, any biosimilar or generic version of such compound that is not controlled by Collaborator or its Affiliate.

1.19.

“Collaborator Compound Arm(s)” means any portion of the Collaborator Clinical Trial where patients are intended to receive the Collaborator Compound either alone or in concomitant or sequential administration with one or more treatments, but not in combination with the MSD Compound.

1.20.

“Collaborator Escalation Contact” means the person set forth in the “Collaborator JDC Escalation Person Title” row of the Information Sheet.

1.21.

“Collaborator Inventions” means all Inventions relating to or covering the Collaborator Compound or a Collaborator Class Compound, and not relating to or covering the MSD Compound or a PD-1 Antagonist, including all improvements related thereto, regardless of whether such Invention was invented solely by Collaborator or MSD or jointly by the Parties.

1.22.

“Combination” means the use or method of using the Collaborator Compound and the MSD Compound in concomitant or sequential administration (whether or not in concomitant or sequential administration with one or more other treatments). “Sequential administration” shall not include separate but sequential lines of therapy.

1.23.

“Combination Arm(s)” means the portion of the Collaborator Clinical Trial where patients are intended to receive the Collaborator Compound and the MSD Compound in Combination (whether or not in concomitant or sequential administration with one or more other treatments).

1.24.

“Compounds” means the Collaborator Compound and the MSD Compound. A “Compound” means either the Collaborator Compound or the MSD Compound.

1.25.

“Confidential Information” means any information (including personal data), Know-How or other proprietary information or materials furnished to a Receiving Party by or on behalf of a Disclosing Party in connection with this Agreement, except to the extent that such information or materials, as demonstrated by competent evidence: (i) was already known to the Receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the Disclosing Party; (ii) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party; (iii) became generally available to the public or otherwise part of the public domain after its disclosure and other than through a breach of this Agreement by the Receiving Party; (iv) was disclosed to the Receiving Party by a Third Party who had no obligation to the Disclosing Party not to disclose such information to others; or (v) was subsequently developed by the Receiving Party without use of the Disclosing Party’s Confidential Information. MSD Clinical Data is deemed the Confidential Information of MSD (and MSD is the “Disclosing Party” and Collaborator the “Receiving Party” with respect to the same). Collaborator Clinical Data is deemed the Confidential Information of Collaborator (and Collaborator is the “Disclosing Party” and MSD the “Receiving Party” with respect to the same). Joint Clinical Data is deemed to be the Confidential Information of both Parties.

1.26.

“Continuing Party” means the Party continuing prosecution or maintenance pursuant to Section 10.4 (Declining to File, Prosecute or Maintain).

1.27.

“Control” or “Controlled” means, with respect to particular information or intellectual property, that the applicable Party or its Affiliate owns or has a license to such information or intellectual property and has the ability to grant a right, license or sublicense as provided for herein without violating the terms of any agreement or other arrangement with any Third Party.

1.28.

“CTA” means an application to a Regulatory Authority for purposes of requesting the ability to start or continue a clinical trial.

1.29.

“Data Protection Law” means any applicable data protection or privacy law to which a Party is subject in connection with this Agreement.

1.30.

“Data Protection Terms” means Exhibit C hereto, which ensures certain protections are in place for the processing personal data in the performance of the MSD Compound Study and sets forth the Parties’ responsibilities for certain obligations, including addressing the rights of data subjects, ensuring a legal basis for processing personal data, conducting appropriate data-protection impact assessments and prior consultations with relevant supervisory authorities, complying with all personal-data breach-notification obligations, and certain other compliance obligations under Data Protection Law.

1.31.

“Data Sharing Schedule” means the schedule attached hereto as Schedule I.

1.32.

“Defending Party” means a Party controlling the defense of an action pursuant to Section 14.2.3 (Procedure).

1.33.

“Delivery” means, with respect to a given quantity of (i) the MSD Compound, when such Compound is delivered, ready for unloading, at the Collaborator’s named place of destination in accordance with DAP (Incoterms 2020) and, (ii) the Collaborator Compound, when such Compound is packaged for shipment to an MSD Compound Study site. “Deliver” shall have a correlative meaning.

1.34.

“Disclosing Party” means a Party (or its Affiliate) disclosing Confidential Information of such Party hereunder.

1.35.

“Effective Date” means the date set forth in the “Effective Date” row of the Information Sheet.

1.36.

“EMA” means the European Medicines Agency and any successor agency.

1.37.

“Exclusions List” means: (i) List of Excluded Individuals and Entities on the U.S. Department of Health and Human Services, Office of Inspector General (OIG) website including 42 U.S.C. 1320a-7 (▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇.▇▇▇/▇▇▇▇▇▇▇▇▇▇/▇▇▇▇▇.▇▇▇); (ii) the U.S. General Services Administrator’s list of Parties Excluded from Federal Programs – System for Award Management (▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/▇▇▇/▇▇▇▇▇/▇▇▇▇▇▇/▇▇▇▇▇▇▇▇▇▇▇▇▇/▇▇▇▇▇▇.▇▇▇) and (iii) the debarment list promulgated under 21 U.S.C.335a (▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/▇▇▇▇▇▇▇▇▇▇▇- compliance-enforcement-and-criminal-investigations/compliance-actions-and- activities/fda-debarment-list-drug-product-applications.

1.38.

“FCPA” means the U.S. Foreign Corrupt Practices Act.

1.39.

“FDA” means the United States Food and Drug Administration.

1.40.

“Freedom-to-Operate License” means a license to be granted by a Party to the other Party in the event this Agreement is amended or a new agreement is negotiated for the purpose of conducting a Subsequent Study in accordance with Section 2.9.

1.41.

“GCP” means the Good Clinical Practices officially published by EMA, FDA and the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use that may be in effect from time to time and applicable to the testing of the Compounds.

1.42.

“Government Official” means: (i) any officer or employee of a government or any department, agency or instrument of a government; (ii) any Person acting in an official capacity for or on behalf of a government or any department, agency, or instrument of a government; (iii) any officer or employee of a company or business owned in whole or part by a government; (iv) any officer or employee of a public international organization such as the World Bank or United Nations; (v) any officer or employee of a political party or any Person acting in an official capacity on behalf of a political party; or (vi) any candidate for political office; who, in each of the foregoing cases (i) through (vi), when such Government Official is acting in an official capacity or in an official decision-making role, has responsibility for performing regulatory inspections, government authorizations or licenses, or otherwise has the capacity to make decisions with the potential to affect the business of either Party.

1.43.

“IND” means any Investigational New Drug Application as described in Title 21 of the U.S. Code of Federal Regulations, Part 312, and the equivalent application in the jurisdictions outside the United States, including an “Investigational Medicinal Product Dossier” in the European Union.

1.44.

“Information Sheet” means the table entitled Information Sheet set forth just before the preamble to this Agreement.

1.45.

“Inventions” means all inventions and discoveries, whether or not patentable, that are made, conceived, or first actually reduced to practice by or on behalf of a Party, or by or on behalf of the Parties together: (i) in the design or performance of the MSD Compound Study or in the design or performance of any Subsequent Study performed pursuant to Section 2.9 (Subsequent Study); (ii) through use of unpublished Clinical Data; or (iii) through use of Sample Testing Results that are to be shared between the Parties pursuant to the Sample Testing Schedule.

1.46.

“Joint Clinical Data” means all data (including raw data) and results generated by or on behalf of either Party or at either Party’s direction, or by or on behalf of the Parties together or at their direction, in the course of the Combination Arm(s); provided however, that Joint Clinical Data does not include Sample Testing Results, Collaborator Clinical Data or MSD Clinical Data.

1.47.

“Joint Development Committee” or “JDC” means the committee to be established by the Parties pursuant to Section 2.3 (Joint Development Committee; Managers).

1.48.

“Joint Patent” means a Patent with respect to any Joint Invention.

1.49.

“Joint Invention” means any Inventions relating to or covering the combined use of the Collaborator Compound and the MSD Compound that are not MSD Inventions or Collaborator Inventions.

1.50.

“Kit” means a single vial of MSD ▇▇▇▇▇▇▇▇, as detailed in the pro-forma invoice that accompanies the MSD Compound for which MSD is entitled to reimbursement pursuant to Sections 6.10 (Manufacturing Costs) or 8.9.2 (Non-Conformance).

1.51.

“Know-How” means any proprietary invention, innovation, improvement, development, discovery, computer program, device, trade secret, method, know-how, process, technique or the like, including manufacturing, use, process, structural, operational and other data and information, whether or not written or otherwise fixed in any form or medium, regardless of the media on which contained and whether or not patentable or copyrightable, that is not generally known or otherwise in the public domain.

1.52.

“Liability” means any loss, damage, reasonable costs and expenses (including reasonable attorneys’ fees and expenses) incurred in connection with any claim, proceeding, or investigation by a Third Party arising out of this Agreement or the Collaborator Clinical Trial.

1.53.

“Manufacture,” “Manufactured,” or “Manufacturing” means all activities related to the manufacture of a Compound, including planning, purchasing, manufacture, processing, compounding, storage, filling, packaging, waste disposal, labeling, leafleting, testing, quality assurance, sample retention, stability testing, release, dispatch and supply.

1.54.

“Manufacturer’s Release” or “Release” has the meaning ascribed to release of the MSD Compound in the Clinical Quality Agreement.

1.55.

“Manufacturing Site” means the facilities where a Compound is Manufactured by or on behalf of a Party.

1.56.

“MSD” has the meaning set forth in the preamble to this Agreement.

1.57.

“MSD Background Patents” means any Patent Controlled by MSD or its Affiliate that claims or covers the Combination and is not a Joint Patent.

1.58.

“MSD Clinical Data” means all data (including raw data) and results generated by or on behalf of either Party or at either Party’s direction, or by or on behalf of the Parties together or at their direction, in the course of the MSD Compound Arm(s), if any MSD Compound Arm(s) are included in the Collaborator Clinical Trial; provided however, that MSD Clinical Data does not include Sample Testing Results, Joint Clinical Data or Collaborator Clinical Data.

1.59.

“MSD Compound” means pembrolizumab, a humanized anti-human PD-1 monoclonal antibody, excluding, however, any biosimilar version of pembrolizumab that is not controlled by MSD or its Affiliate.

1.60.

“MSD Compound Arm(s)” means any portion of the Collaborator Clinical Trial where patients are intended to receive the MSD Compound either alone or in combination with one or more treatments but not in Combination with the Collaborator Compound.

1.61.

“MSD Compound Study” means the arms of the Collaborator Clinical Trial where patients are intended to receive the MSD Compound either alone or in combination with one or more treatments (including the Collaborator Compound). The MSD Compound Study includes the Combination Arm(s) and any MSD Compound Arm(s) included in the Collaborator Clinical Trial.

1.62.

“MSD Compound Study Completion” means: (i) the date when the last patient enrolled in the MSD Compound Study has completed their last study-related assessment for evaluation excluding survival follow-up; or (ii) an alternative date as agreed to by the JDC in writing.

1.63.

“MSD Inventions” means all Inventions related to or covering the MSD Compound or a PD-1 Antagonist, and not related to or covering the Collaborator Compound or a Collaborator Class Compound, and any improvements related thereto, regardless of whether such Invention was invented solely by MSD or Collaborator or jointly by the Parties.

1.64.

“NDA” means a New Drug Application, Biologics License Application, Marketing Authorization Application, filing pursuant to Section 510(k) of the United States Federal Food, Drug and Cosmetic Act, or similar application or submission for a marketing authorization of a product filed with a Regulatory Authority to obtain marketing approval for a biological, pharmaceutical or diagnostic product in a country or group of countries.

1.65.

“Non-Conformance” means, with respect to a given unit of Compound: (i) an event that deviates from an approved cGMP requirement with respect to the applicable Compound, such as a procedure, Specification, or operating parameter, or that requires an investigation to assess impact to the quality of the applicable Compound; or (ii) that such Compound failed to meet the applicable representations and warranties set forth in Article 8 (Supply and Use of Compounds) or Section 13.2 (Compounds). “Non- Conforming” shall have a correlative meaning.

1.66.

“Non-Pursuing Party” means a Party not pursuing the filing, prosecution or maintenance of a Joint Patent pursuant to Section 10.4 (Declining to File, Prosecute or Maintain).

1.67.

“Opting-out Party” means a Party that wishes to discontinue the prosecution and maintenance of a Joint Patent pursuant to Section 10.4 (Declining to File, Prosecute or Maintain).

1.68.

“Other Party” means a Party not controlling the defense of an action pursuant to Section 14.2.3 (Procedure).

1.69.

“Parties” and “Party” have the meanings set forth in the preamble to this Agreement.

1.70.

“Patent” means (a) a patent application, (b) any additions, priority applications, divisions, continuations, and continuations-in-part of the patent application, and (c) all patents issuing on any of the foregoing patent applications, together with all invention certificates, substitutions, reissues, reexaminations, registrations, supplementary protection certificates, confirmations, renewals, and extensions of any of (a), (b), or (c), in any and all jurisdictions worldwide.

1.71.

“PD-1 Antagonist” means any small or large molecule that blocks binding of PD-L1 or PD- L2 to PD-1.

1.72.

“Person” means any entity, including any individual, sole proprietorship, partnership, corporation, business trust, joint stock company, trust, unincorporated organization, association, limited liability company, institution, public benefit corporation, joint venture, or governmental entity.

1.73.

“Pharmacovigilance Agreement” means the pharmacovigilance agreement to be executed by the Parties pursuant to Section 2.6 (Pharmacovigilance Agreement).

1.74.

“Project Manager” means the Project Managers to be designated by the Parties pursuant to Section 2.3 (Joint Development Committee; Managers).

1.75.

“Protocol” means the written documentation that describes the Collaborator Clinical Trial and sets forth specific activities to be performed as part of the conduct of the Collaborator Clinical Trial.

1.76.

“Pursuing Party” means a Party pursuing the filing, prosecution or maintenance of a Joint Patent pursuant to Section 10.4 (Declining to File, Prosecute or Maintain).

1.77.

“Receiving Party” means a Party (or its Affiliate) receiving Confidential Information of the other Party hereunder.

1.78.

“Regulatory Approvals” means, with respect to a Compound, any and all permissions (other than the Manufacturing approvals) required to be obtained from any Regulatory Authority or other competent authority for the development, registration, importation and distribution of such Compound in any jurisdiction for use in the MSD Compound Study.

1.79.

“Regulatory Authorities” means the FDA, national regulatory authorities, the EMA, any successor agency to the FDA or EMA and any agency or authority performing some or all of the functions of the FDA or EMA in any jurisdiction.

1.80.

“Regulatory Documentation” means all submissions to Regulatory Authorities in connection with the development of a Compound, including all INDs and amendments thereto, CTAs and amendments thereto, NDAs and amendments thereto, drug master files, correspondence with regulatory agencies, periodic safety update reports, adverse- event files, complaint files, inspection reports and manufacturing records, in each case together with all supporting documents (including any documents that include Clinical Data).

1.81.

“Related Agreements” means the Pharmacovigilance Agreement, and the Clinical Quality Agreement.

1.82.

“Related Entities” means, with respect to each of Collaborator and MSD, such Party’s Affiliates and its and their directors, officers, employees and others acting on its or their behalf, including their respective Subcontractors.

1.83.

“Right of Reference” means the “right of reference” defined in 21 CFR 314.3(ii) including, with regard to a Party, allowing the applicable Regulatory Authority in a country to have access to relevant information and data (by cross-reference, incorporation by reference or otherwise) contained in Regulatory Documentation filed with such Regulatory Authority with respect to a Party’s Compound.

1.84.

“SAE” means a serious adverse event.

1.85.

“Samples” means biological specimens collected from subjects participating in the MSD Compound Study, including any urine, blood and tissue samples.

1.86.

“Sample Testing” means the analyses to be performed by each Party using the applicable Samples, as described in the Sample Testing Schedule.

1.87.

“Sample Testing Results” means the data and results arising from the Sample Testing.

1.88.

“Sample Testing Schedule” means the schedule attached hereto as Schedule II.

1.89.

“Sensitive Information” means unpublished Joint Clinical Data, MSD Clinical Data, Sample Testing Results generated by MSD and Confidential Information relating to MSD Inventions, the MSD Compound or the Combination.

1.90.

“Specifications” means the requirements to which a Compound must conform. The Specifications for a Compound will be set forth in the certificate of analysis accompanying each batch of Compound supplied for use in the MSD Compound Study.

1.91.

“Subcontractors” means any and all Third Parties to whom a Party delegates any of its obligations hereunder.

1.92.

“Subsequent Study” means a registrational study for the Combination in the same indication(s) and line(s) of therapy as that included in the Combination Arm(s).

1.93.

“Sunshine Act” shall mean the Physician Payments Sunshine Act as amended from time to time.

1.94.

“Term” means the term of this Agreement.

1.95.

“Third Party” means any Person or entity other than Collaborator, MSD or their respective Affiliates.

1.96.

“Third-Party Infringement” means any actual or threatened infringement or misappropriation by a Third Party of any Joint Patent or Joint Invention.

1.97.

“Toxicity and Safety Data” means all clinical adverse-event information or patient-related safety data included in the Joint Clinical Data and MSD Clinical Data, as more fully described in the Pharmacovigilance Agreement.

1.98.

“Transparency Report” means a transparency report in connection with reporting payments and other transfers of value made to health-care professionals, including investigators, steering-committee members, data-monitoring committee members, and consultants in connection with the MSD Compound Study in accordance with reporting requirements under Applicable Law, including the Sunshine Act and state gift laws, and the European Federation of Pharmaceutical Industries and Associations Disclosure Code, and a Party’s applicable policies.

1.99.

“VAT” means a value-added or similar tax.

1.100.

“Violation” means that a Party or any of its officers or directors or any other personnel (or other permitted agents of a Party performing activities hereunder) has been: (i) convicted of any of the felonies identified among the Exclusion Lists or (ii) identified or listed as having an active exclusion on any Exclusion List; or (iii) listed by any US Federal agency as being suspended, proposed for debarment, debarred, excluded or otherwise ineligible to participate in Federal procurement or non-procurement programs, including under any Exclusion List.

PERFORMANCE OF THE AGREEMENT. RELATED AGREEMENTS.

2.1.

The Collaborator Clinical Trial. Collaborator is conducting or intends to conduct the Collaborator Clinical Trial, which Collaborator Clinical Trial has or is intended to have a Combination Arm(s). In addition, the Collaborator Clinical Trial may (or may not) have a Collaborator Compound Arm(s), an MSD Compound Arm(s), or both. The term “Collaborator Clinical Trial” as used in this Agreement refers to the Collaborator Clinical Trial as a whole, including the Combination Arm(s), and any Collaborator Compound Arm(s) or MSD Compound Arm(s) that form or are intended to form a part of the Collaborator Clinical Trial. The term “MSD Compound Study” refers to the Combination Arm(s) and any MSD Compound Arm(s) that form or are intended to form a part of the Collaborator Clinical Trial. Collaborator Clinical Trial, Collaborator Compound Arm(s), Combination Arm(s), MSD Compound Arm(s) and MSD Compound Study all refer to such arms as are intended to be conducted in accordance with the Protocol, including the Protocol as may be amended in accordance with Article 4 (PROTOCOL AND INFORMED CONSENT; CERTAIN COVENANTS).

2.2.

Generally. Each Party shall: (i) contribute such resources as are necessary to conduct the activities contemplated by this Agreement; and (ii) act in good faith in performing its obligations under this Agreement and each Related Agreement to which it is a Party.

2.3.

Joint Development Committee; Managers; Escalation.

2.3.1.

The Parties shall form the Joint Development Committee made up of an equal number of representatives of MSD and Collaborator, which shall have responsibility for coordinating all regulatory and other activities under, and pursuant to, this Agreement (except for activities under, and pursuant to, Article 10 (INTELLECTUAL PROPERTY)). Representatives of MSD and Collaborator on the JDC shall be entitled to one collective vote on behalf of each of MSD and Collaborator, respectively, on all matters upon which the JDC have the right to decide under this Agreement. Each Party shall designate a Project Manager who shall be responsible for implementing and coordinating activities and facilitating the exchange of information between the Parties with respect to the MSD Compound Study and shall be entitled to attend meetings of the JDC. JDC members will be agreed by both Parties.

2.3.2.

The JDC shall meet a minimum of two (2) times per year, unless otherwise agreed by the JDC, to provide an update on the progress of the MSD Compound Study. The JDC may meet in person or by means of teleconference, internet conference, videoconference or similar means. Prior to any such meeting, ▇▇▇▇▇▇▇▇▇▇▇▇’s Project Manager shall provide a written update to MSD’s Project Manager and Alliance Manager containing information about the overall progress of the MSD Compound Study, recruitment status, interim analysis (if available), final analysis and other information relevant to the conduct of the MSD Compound Study (and data relating to the Collaborator Clinical Trial reasonably requested by MSD and relevant to the MSD Compound Study).

2.3.3.

In addition to a Project Manager, each Party shall designate an Alliance Manager who shall serve as the primary point of contact for any issues arising under this Agreement and shall endeavor to ensure clear and responsive communication and the effective exchange of information between the Parties. The Alliance Managers shall have the right to attend all JDC meetings and may bring to the attention of the JDC any matters either of them reasonably believes should be discussed and shall have such other responsibilities as the Parties may mutually agree.

2.3.4.

In the event that (i) an issue arises and the Alliance Managers do not, after good faith efforts, reach agreement on such issue, (ii) there is a decision to be made by the JDC on which the members of the JDC do not agree, or (iii) the Parties cannot agree on a matter in respect of the Protocol, the issue shall be elevated to the Senior Vice President of Clinical Research for MSD and the Collaborator Escalation Contact. In the event such escalation does not result in resolution or consensus: (x) MSD shall have final decision-making authority with respect to issues related to MSD Compound; and (y) Collaborator shall have final decision-making authority with respect to issues related to Collaborator Compound.

2.4.

Clinical Quality Agreement. The Parties will execute the Clinical Quality Agreement prior to any supply of MSD ▇▇▇▇▇▇▇▇ hereunder, and no later than forty-five (45) days after the Effective Date. The Clinical Quality Agreement shall, among other things: (i) detail classification of any Non-Conforming MSD Compound; (ii) include criteria for Manufacturer’s Release and related certificates and documentation; (iii) include criteria and timeframes for acceptance of MSD Compound; (iv) include procedures for the resolution of disputes regarding any Non-Conforming MSD Compound; (v) detail procedures and rights with respect to audit and inspection rights for Manufacturing sites; and (vi) include provisions governing the recall of Compounds. Quality matters and the Manufacture of the MSD Compound shall be governed by the terms of the Clinical Quality Agreement in addition to the relevant quality provisions of this Agreement.

2.5.

Data Protection. The Parties will comply with the Data Protection Terms set forth on Exhibit C, which are incorporated into and form a part of this Agreement.

2.6.

Pharmacovigilance Agreement. The Parties will execute the Pharmacovigilance Agreement prior to MSD Delivering MSD Compound to Collaborator hereunder. The Pharmacovigilance Agreement will: (i) include safety data exchange procedures; (ii) facilitate appropriate safety reviews; (iii) govern the coordination of collection, investigation, reporting, and exchange of information concerning any adverse experiences, pregnancy reports, and any other safety information arising from or related to the use of the MSD Compound and Collaborator Compound in the MSD Compound Study; and (iv) enable the Parties and their Affiliates to fulfill local and international regulatory reporting obligations to Regulatory Authorities, all of the foregoing in accordance with Applicable Law. For the avoidance of doubt, the obligations to provide safety data under the Pharmacovigilance Agreement will be independent of any obligations to provide safety data pursuant to this Agreement.

2.7.

Delegation of Obligations. Each Party shall have the right to delegate any portion of its obligations hereunder only: (i) to such Party’s Affiliates; (ii) to Third Parties that are set forth on Schedule III as performing MSD Compound Study activities or as conducting Sample Testing for such Party; (iii) to the extent related to the Manufacture of such Party’s Compound; and (iv) upon the other Party’s prior consent. Notwithstanding any delegation of its obligations hereunder, each Party shall remain solely and fully liable for the performance of its Affiliates and Subcontractors under this Agreement. Each Party shall ensure that each of its Affiliates and Subcontractors performs such Party’s obligations pursuant to the terms of this Agreement. Each Party shall use reasonable efforts to obtain and maintain copies of documents relating to the obligations performed by its Affiliates and Subcontractors that are required to be provided to the other Party under this Agreement.

2.8.

Relationship. Without prejudice to Section 2.9 (Subsequent Study), this Agreement does not create any obligation for either Party to provide any compound other than its Compound or to provide its Compound for any activities other than the MSD Compound Study. Except as expressly set forth in Section 2.9 (Subsequent Study), nothing in this Agreement shall: (i) prohibit either Party from performing other clinical studies with its own Compound, either individually or in combination with any other compound or product, in any therapeutic area; or (ii) create an exclusive relationship between the Parties with respect to any Compound. Each Party acknowledges and agrees that nothing in this Agreement shall be construed as a representation or inference that the other Party will not develop for itself, or enter into business relationships with other Third Parties regarding, any products, programs, studies (including combination studies), technologies or processes that are similar to or that may compete with the Combination or any other product, program, technology or process, including Collaborator Class Compounds or PD- 1 Antagonists, provided that the Joint Clinical Data, Confidential Information, Joint Inventions and Sample Testing Results are not used or disclosed in connection therewith in violation of this Agreement. Notwithstanding the foregoing, and notwithstanding any implication to the contrary in this Agreement, Collaborator shall have no right to include any PD-1 Antagonist other than the MSD Compound in the Collaborator Clinical Trial. Collaborator and MSD have no obligation to renew this Agreement or apply this Agreement to any clinical trial other than the Collaborator Clinical Trial. Except as expressly set forth in Section 2.9 (Subsequent Study), nothing in this Agreement obligates the Parties to enter into any agreement other than the Related Agreements now or in the future.

2.9.

Subsequent Study. During the Term and for a period of twelve (12) months thereafter, either Party shall have the option to propose amending this Agreement (and the Related Agreements as necessary) or negotiating a new agreement, as appropriate, for the purpose of conducting a Subsequent Study. During such time period, Collaborator must offer MSD the option of participating in a Subsequent Study no less than sixty (60) days prior to entering into an agreement with a Third Party to conduct a registrational study of the Collaborator Compound in combination with a PD-1 Antagonist in the same indication(s) and line(s) of therapy as the MSD Compound Study. Following receipt of a proposal for a Subsequent Study, the Parties shall negotiate in good faith the terms of such amendment or new agreement. Neither Party will have any obligation to agree upon the details of or execute any such amendment or agreement; provided, however, in the event this Agreement is amended or a new agreement is negotiated for the purpose of conducting a Subsequent Study, the Parties shall grant to each other a non-exclusive, worldwide, royalty-free, fully paid-up, transferable, and sublicensable license to any Patent Controlled by a Party or its Affiliate that claims or covers the Combination and is not a Joint Patent under the amended Agreement or the new agreement solely for the purpose of: (i) conducting the Subsequent Study, (ii) researching and developing the Combination in the same indication as the Combination Arm during the term of the amended Agreement or the new agreement, and (iii) obtaining and promoting an initial or an updated label indication for the Combination in the same indication as the Combination Arm during the longer of the Term and the life of such Patents (“Freedom- to-Operate License”). Notwithstanding such Freedom-to-Operate License, in no event shall: (i) MSD have the right to exploit such licensed Patents to sell any Collaborator Class Compound, either alone or as part of a combination (including the Combination); or (ii) Collaborator have the right to exploit such licensed Patents to sell any PD-1 Antagonist, either alone or as part of a combination (including the Combination).

CONDUCT OF THE MSD COMPOUND STUDY.

3.1.

Sponsor. Collaborator shall act as the sponsor of the Collaborator Clinical Trial under its own IND for the Collaborator Compound with a Right of Reference to the IND of the MSD ▇▇▇▇▇▇▇▇ as described in Section 3.5 (Regulatory Matters); provided, however, that in no event shall Collaborator file an additional IND for the MSD Compound Study unless required by Regulatory Authorities to do so. If a Regulatory Authority requests such an additional IND for the MSD Compound Study, the Parties shall meet and agree on an approach to address such requirement.

3.2.

Clinical Safety Data Review. If the Information Sheet indicates that this Agreement contains a safety gate (i.e. “Yes” is selected for the Safety Gate (Yes/No) row), then this Section 3.2 (Clinical Safety Data Review) shall apply to this Agreement. If “No” is selected, for such Safety Gate row, then this Section 3.2 (Clinical Safety Data Review) shall be deemed omitted from this Agreement and shall not apply. Prior to dosing any patient with the MSD Compound in the Combination Arm(s), Collaborator shall invite MSD to attend a safety review meeting, during reasonable business hours, to review the most recent Clinical Safety Data (and other data reasonably requested by MSD to evaluate the safety of the proposed Combination Arm(s)). Collaborator shall provide MSD with reasonable advance notice of such meeting. At such meeting, MSD shall have the opportunity to review such Clinical Safety Data. Collaborator shall also provide MSD with a copy of such Clinical Safety Data for further review. The decision to proceed with the MSD Compound Study requires the mutual consent of the Parties in each Party’s sole discretion. If, following review of such Clinical Safety Data, either Party notifies the other Party that it does not want to proceed with the MSD Compound Study, then this Agreement shall terminate in accordance with Section 6.4 (Termination for Patient Safety). On an ongoing basis during the Term, Collaborator shall invite MSD to attend its safety review meetings and provide to MSD an updated copy of all Clinical Safety Data. Following review of such Clinical Safety Data and discussion at the JDC, if MSD determines that the Collaborator Clinical Trial or the MSD Compound Study may adversely affect patient safety, MSD may discontinue the MSD Compound Study by so notifying Collaborator and may terminate this Agreement in accordance with Section 6.4 (Termination for Patient Safety). For the avoidance of doubt, the obligations to provide Clinical Safety Data under this Section 3.2 will be independent of any obligations to provide safety data pursuant to any other provisions contained in this Agreement or otherwise.

3.3.

Performance. Collaborator shall ensure that the MSD Compound Study and all related activities are performed in accordance with this Agreement, the Protocol and all Applicable Law, including GCP.

3.4.

Debarred Personnel; Exclusions Lists. Collaborator certifies that it has not and shall not use in any capacity the services of any person, including any subcontractor or individual, that has been excluded, debarred, suspended, proposed for suspension or debarment, in Violation or otherwise ineligible for government programs including Title 21 U.S.C. Section 335a or any foreign equivalent thereof. Collaborator has, as of the Effective Date screened itself, and its Affiliates’ officers and directors against the Exclusions Lists and has informed MSD whether it or any of its employees, officers or directors is or has been in Violation. Collaborator shall notify MSD in writing immediately if any suspension, proposed debarment, debarment or Violation occurs or comes to its attention with respect to any Person performing activities related to the MSD Compound Study or otherwise related to activities under this Agreement.

3.5.

Regulatory Matters. Collaborator shall: (i) obtain all Regulatory Approvals from all Regulatory Authorities, ethics committees and institutional review boards with jurisdiction over the MSD Compound Study prior to its initiation; and (ii) follow all directions from any such Regulatory Authorities, ethics committees and institutional review boards. MSD shall have the right (but not the obligation) to participate in any discussions (including meetings) with a Regulatory Authority regarding matters related to the MSD Compound Study or the MSD ▇▇▇▇▇▇▇▇ and to collaborate on questions posed to Regulatory Authorities regarding design and conduct of the MSD Compound Study. If a Right of Reference is necessary for the conduct of the MSD Compound Study in a given country, each Party shall provide a cross-reference letter or similar communication to the applicable Regulatory Authority as needed to effectuate the Right of Reference. Notwithstanding anything to the contrary in this Agreement, neither Party shall have any right to access the other Party’s CMC data with respect to such other Party’s Compound. MSD shall authorize the FDA and other applicable Regulatory Authorities to cross- reference the appropriate MSD Compound INDs and CTAs to provide data access to Collaborator as necessary to conduct the MSD Compound Study. If MSD’s CTA is not available in a given country, MSD will file its CMC data with the Regulatory Authority for such country, referencing Collaborator’s CTA as appropriate (however, Collaborator shall have no right to access the CMC data).

3.5.1.

Investigator’s Brochure for MSD Compound. MSD shall provide Collaborator with the current investigator’s brochure for the MSD Compound promptly following the Effective Date and any material updates or changes to the investigator’s brochure for the MSD Compound during the Term for use by Collaborator as needed for regulatory and safety purposes. All versions of MSD’s investigator’s brochure for the MSD ▇▇▇▇▇▇▇▇ provided by MSD to Collaborator shall be MSD Confidential Information.

3.6.

Documentation. Collaborator shall maintain reports and all related documentation in good scientific manner and in compliance with Applicable Law. Collaborator shall provide to MSD all Collaborator Clinical Trial information and documentation reasonably requested by MSD to enable MSD to: (i) comply with any of its legal, regulatory or contractual obligations, or any request by any Regulatory Authority related to the MSD Compound; and (ii) determine whether the MSD Compound Study has been performed in accordance with this Agreement.

3.7.

Copies. Collaborator shall provide to MSD copies of all Joint Clinical Data and any MSD Clinical Data in electronic form or other mutually agreeable alternate form and on the timelines specified in the Data Sharing Schedule or mutually agreed; provided, however, that a complete copy of the Joint Clinical Data and any MSD Clinical Data shall be provided to MSD no later than thirty (30) days following MSD Compound Study Completion or any sooner termination of this Agreement. Collaborator shall ensure that: (i) all patient authorizations and consents required under Applicable Law in connection with the Collaborator Clinical Trial permit such sharing of Joint Clinical Data and any MSD Clinical Data with MSD; and (ii) it complies with Applicable Law in transferring personal data hereunder.

3.8.

Sample Testing.

3.8.1.

Collaborator shall provide Samples to MSD as specified in the Protocol and as agreed to by the Joint Development Committee. Each Party shall use the Samples only for Sample Testing in accordance with the Sample Testing Schedule and the Protocol. Each Party shall own all Sample Testing Results arising from Sample Testing performed by or on behalf of such Party. Solely to the extent specified on the Sample Testing Schedule as being shared, each Party shall provide the other such specified Sample Testing Results for the Sample Testing conducted by it or on its behalf, in electronic form or other form as agreed, on the timelines specified in the Sample Testing Schedule or as otherwise agreed.

3.8.2.

Except to the extent otherwise expressly agreed, each Party may use and disclose the Sample Testing Results owned by and shared by the other Party in accordance with the Sample Testing Schedule solely for the purposes of: (i) seeking regulatory approval for the use of its Compound in the Combination; (ii) filing, prosecution and enforcement of Joint Patents (for both Parties) and Patents with respect to MSD Inventions (for MSD) or Collaborator Inventions (for Collaborator); (iii) conducting Subsequent Studies; and (iv) internal purposes related to its own Compound.

3.9.

Ownership and Use of Joint Clinical Data.

3.9.1.

All Joint Clinical Data shall be jointly owned by Collaborator and MSD. Each Party hereby assigns to the other Party an undivided one-half interest in, to and under the Joint Clinical Data. Where such assignment is precluded by Applicable Law or otherwise does not occur, the Party otherwise obligated to assign such interest hereby grants the other Party a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid-up license to the Joint Clinical Data, with the right to grant sublicenses and to assign such rights to any Person, in each case without the consent of or any obligation of accounting to the granting Party. Collaborator shall maintain the Joint Clinical Data and any MSD Clinical Data in its internal database; provided, however, that at all times during the Term and for ninety (90) days thereafter, Collaborator shall grant MSD access to all Joint Clinical Data and any MSD Clinical Data. If MSD requests access to Collaborator Clinical Data to evaluate the safety or performance of the Combination or to register the MSD Compound in the Combination, Collaborator shall promptly provide MSD with such data.

3.9.2.

All Collaborator Clinical Data shall be solely owned by Collaborator. All MSD Clinical Data shall be solely owned by MSD. In accordance with the foregoing, each Party hereby assigns to the other its entire right, title and interest, if any, in, to and under the MSD Clinical Data (with respect to Collaborator) and the Collaborator Clinical Data (with respect to MSD). Where such assignment is precluded by Applicable Law or otherwise does not occur, the Party otherwise obligated to assign such interest hereby grants the other Party a perpetual, irrevocable, worldwide, royalty-free, fully paid-up exclusive license with the right to grant sublicenses and to assign such rights, to the MSD Clinical Data (with respect to the grant by Collaborator to MSD) and the Collaborator Clinical Data (with respect to the grant by MSD to Collaborator) in each case without the consent of or any accounting to the granting Party.

3.9.3.

Notwithstanding the foregoing, before publication or presentation of a summary of the Joint Clinical Data in accordance with Section 12.2 (Publication), neither Party may disclose the Joint Clinical Data publicly or to a Third Party without the consent of the other Party and each Party’s use of such unpublished Joint Clinical Data is restricted to: (i) seeking regulatory approval for use of such Party’s Compound in the Combination; (ii) filing, prosecution and enforcement of Joint Patents (for both Parties) and Patents with respect to MSD Inventions (for MSD) or Collaborator Inventions (for Collaborator); (iii) conducting Subsequent Studies; and (iv) internal purposes related to its Compound; provided, however, that the foregoing shall not limit or restrict either Party’s ability to: (a) use or disclose the Joint Clinical Data as may be necessary to comply with Applicable Law or with such Party’s internal policies and procedures with respect to pharmacovigilance and adverse event reporting; or (b) share with Third Parties or Affiliates Toxicity and Safety Data where, because of severity, frequency or lack of reversibility, either Party needs to use such Toxicity and Safety Data with respect to its Compound or the Combination to ensure patient safety. For the purposes of this Section 3.9.3, “publication or presentation” includes any publicly-available oral presentation, journal publication, abstract, poster presentation, press release, paper, letter, or other publicly-available publication. For clarity, following publication of the Joint Clinical Data in accordance with Article 12, the restrictions set forth in this Section 3.9.3 shall no longer apply with respect to such published data and any underlying Joint Clinical Data that was necessary for generating the published data and either Party may make subsequent public disclosure of such data, but solely to the extent such subsequent public disclosure is consistent with the contents of such publication or such underlying Joint Clinical Data.

3.9.4.

Notwithstanding anything to the contrary in this Section 3.9 (Ownership and Use of Joint Clinical Data), Collaborator may: (i) share unpublished Clinical Data with Collaborator’s bona fide, potential investors, provided that: (a) such investors are bona fide financial investors and do not have an active role in developing or commercializing pharmaceutical products; and (b) such investors are under obligations of confidentiality and non-use at least as stringent as those set forth in Section 9.1 (Confidential Information) of this Agreement; and (ii) share unpublished Clinical Data with investors (other than bona fide financial investors) and Third Parties interested in a potential license, collaboration or Change of Control transaction with Collaborator, provided that: (x) such investor or Third Party does not own or control a PD-1 Antagonist, does not have the right to develop or commercialize a PD-1 Antagonist of a Third Party and does not have a financial interest in a PD-1 Antagonist of a Third Party (for the avoidance of doubt a passive investment of less than twenty percent (20%) of the equity interest in a company does not, in and of itself, constitute a financial interest in a PD-1 Antagonist, even if such company is researching, developing or commercializing a PD-1 Antagonist); (y) such investor or Third Party must be under obligations of confidentiality and non-use at least as stringent as those set forth in Section 9.1 (Confidential Information) of this Agreement; and (z) Collaborator must notify MSD at least thirty (30) days before such disclosure of the reasons for the planned disclosure and provide MSD with a copy of the Clinical Data (and any related summaries or analyses) to be disclosed. Collaborator will consider MSD’s comments on such Clinical Data, summaries and analyses.

3.10.

Regulatory Submission. It is understood and acknowledged by the Parties that positive Clinical Data may be used to obtain label changes for the Compounds.

3.11.

Certain Memoranda and Reports. Promptly following MSD Compound Study Completion, Collaborator shall provide to MSD an electronic draft of the top-line results memorandum and an electronic draft of the final report of the results of the MSD Compound Study. MSD shall have fifteen (15) days after receipt of such results memorandum and thirty (30) days after receipt of such final report to provide comments thereon. Collaborator shall consider any comments provided by MSD on either document and shall not include any statements in either document relating to the MSD Compound or the MSD Clinical Data that have not been approved by MSD. Collaborator shall deliver to MSD a final version of each such document promptly following finalization thereof.

3.12.

Licensing.

3.12.1.

Nothing in this Agreement shall prohibit or restrict a Party from licensing, assigning or transferring to an Affiliate or Third Party such Party’s Compound or any Inventions, Confidential Information or Sample Testing Results owned solely by such Party.

3.12.2.

A Party may license, assign or transfer to an Affiliate or Third Party, subject to any obligations or restrictions set forth in this Agreement, such Party’s interest in the Joint Clinical Data, Confidential Information owned jointly by the Parties or Joint Inventions, and, in connection therewith, share the shared Sample Testing Results owned by the other Party, solely to the extent such licensee, assignee or transferee agrees to be bound by the terms of this Agreement with respect to the licensed, assigned or transferred interest which agreement shall be in writing with respect to any license, assignment or transfer to a Third Party.

PROTOCOL AND INFORMED CONSENT; CERTAIN COVENANTS.

4.1.

Protocol. The agreed initial Protocol, or a synopsis, and any agreed draft statistical analysis plan for the MSD Compound Study or Collaborator Clinical Trial are attached hereto as Exhibit A. Collaborator shall: (i) provide a draft of the Protocol (and any subsequent revisions thereof) to MSD for MSD’s review and comment; (ii) consider any changes to the draft of the Protocol requested by MSD; (iii) incorporate any changes requested by MSD with respect to MSD Compound; and (iv) submit the draft Protocol to MSD for final approval. The country or countries in which the MSD Compound Study will be performed will be reviewed and agreed upon by the Parties before MSD Compound Study initiation and any changes thereto will be subject to review and approval of MSD; provided, however that MSD will be deemed to have consented to Collaborator performing the MSD Compound Study in the countries identified on Exhibit D. To the extent the Parties cannot agree regarding the contents of the Protocol for final approval: (x) Collaborator shall have final decision-making authority with respect to matters in the Protocol related to the Collaborator Compound; (y) MSD shall have final decision-making authority with respect to matters in the Protocol related to the MSD Compound (including with respect to the quantities or presentations of MSD Compound to be provided for the MSD Compound Study or the timing for Delivery thereof); and (z) all other matters in respect of the Protocol on which the Parties cannot agree shall be resolved in accordance with Section 2.3 (Joint Development Committee; Managers; Escalation). Notwithstanding anything to the contrary contained herein, each Party, in its sole discretion, shall have the sole right to determine the dose and dosing regimen for its Compound and shall have the final decision on all matters relating to its Compound and any information regarding its Compound included in the Protocol.

4.2.

Informed Consent. Collaborator shall prepare the patient informed-consent form for the MSD Compound Study (which shall include provisions regarding the use of Samples in Sample Testing) in consultation with MSD (it being understood and agreed that the portion of the informed-consent form relating to the Sample Testing of the MSD Compound shall be provided to Collaborator by MSD and adopted by Collaborator).

4.3.

Changes to Protocol or Informed Consent. Any proposed changes to: (i) the approved final Protocol (other than changes that are solely related to Collaborator Compound); or (ii) the informed consent form relating to the MSD Compound, including Sample Testing of the MSD Compound, shall be made only with MSD’s prior written consent. Any proposed changes (including those which do not require MSD’s consent) will be sent to MSD’s Project Manager and MSD’s Alliance Manager. For those changes requiring MSD’s consent, MSD will provide such consent, or a written explanation for why such consent is being withheld, within fifteen (15) Business Days after MSD receives a copy of the requested changes. If Protocol revisions made in accordance with this Section 4.3 would necessitate corresponding revisions to the definitions of Collaborator Clinical Trial, Combination Arm(s) or MSD Compound Study, such definitions shall be deemed to be revised consistent with such Protocol revisions.

4.4.

Transparency Reporting. Collaborator is solely responsible for reporting payments and other transfers of value, (including supply of MSD Compound), made to health-care professionals, including investigators, steering-committee members, data-monitoring committee members, and consultants in connection with the MSD Compound Study in accordance with reporting requirements under Applicable Law, including the Sunshine Act and state gift laws, and the European Federation of Pharmaceutical Industries and Associations Disclosure Code, and Collaborator’s applicable policies. Promptly after the Effective Date, Collaborator will notify MSD of Collaborator’s point of contact for purposes of receiving information from MSD pursuant to this Section 4.4, along with such contact’s full name, email address, and telephone number. Collaborator may update such contact from time to time by notifying MSD pursuant to Article 22 (NOTICES). Where applicable, MSD will provide to such Collaborator contact all information regarding the value of the MSD Compound provided for use in the MSD Compound Study as required for such reporting. In the event that the value of the MSD ▇▇▇▇▇▇▇▇ provided pursuant to this Section 4.4 materially changes, MSD shall notify Collaborator of such revised value and the effective date thereof.

4.4.1.

Periods Collaborator is Not Required to Report. With respect to any annual reporting period in which Collaborator is not an entity that is required to make a Transparency Report under Applicable Law, Collaborator will: (i) notify MSD within thirty (30) days after the commencement of such reporting period that Collaborator is not so required; and (ii) during such reporting period Collaborator will track and provide to MSD data regarding “indirect” payments or other transfers of value by Collaborator to health care professionals to the extent such payments or other transfers of value were required, instructed, directed or otherwise caused by MSD pursuant to this Agreement in the format requested by MSD and provided on a basis to be agreed upon by the Parties. Collaborator represents and warrants that any data provided by Collaborator to MSD pursuant to this Section 4.4 will be complete and accurate to the best of Collaborator’s knowledge.

4.5.

Financial Disclosure. To the extent required by Applicable Law, Collaborator will be responsible for preparing and submitting the Financial Disclosure Module 1.3.4 components to the FDA for any Regulatory Documentation in connection with the Collaborator Clinical Trial.

ADVERSE EVENT REPORTING.

5.1.

Pharmacovigilance. Collaborator will be solely responsible for safety reporting for the Collaborator Clinical Trial and related activities, all in accordance with Applicable Law.

5.2.

Transmission of SAEs. Collaborator will transmit to MSD all SAEs from the MSD Compound Study as set forth below. All cases will be transmitted on a CIOMS-1 form in English.

5.2.1.

For fatal and life-threatening SAEs, Collaborator will transmit a processed case within five (5) calendar days after receipt by Collaborator of notice of such SAEs.

5.2.2.

For all other SAEs and newly diagnosed cancer, Collaborator will transmit a processed case within seven (7) calendar days after receipt by Collaborator of notice of such SAEs.

5.2.3.

Cases of disease progression will be handled as outlined in the Protocol, and if the Protocol specifies that such cases are collected as SAEs, Collaborator will transmit such cases to MSD within the applicable timeframe set forth in Section 5.2.1 or Section 5.2.2.

5.2.4.

For all other reportable information that includes: (i) overdose, exposure during pregnancy or lactation; and (ii) cases of potential drug-induced liver injury where the patient was exposed to the MSD Compound (if required to be collected or identified per the Protocol), Collaborator will transmit a processed case within ten (10) calendar days after receipt by Collaborator of such information.

TERM AND TERMINATION.

6.1.

Term. The Term shall commence on the Effective Date and shall continue in full force and effect until delivery of final documents by Collaborator pursuant to Section 3.11 (Certain Memoranda and Reports), unless terminated earlier by either Party pursuant to this Article 6.

6.2.

MSD Termination for Unsafe Use. In the event MSD notifies Collaborator that it in good faith believes that the MSD ▇▇▇▇▇▇▇▇ is being used unsafely in the MSD Compound Study and the grounds for such belief, and if either MSD believes such matter is not reasonably capable of remedy or if Collaborator fails to promptly remedy such issue to MSD’s reasonable satisfaction, MSD may terminate this Agreement and the supply of the MSD Compound by notice to Collaborator with immediate effect.

6.3.

Termination for Breach. Either Party may terminate this Agreement by notice with immediate effect if the other Party commits a material breach of this Agreement and such material breach continues for thirty (30) days after receipt of notice thereof from the non- breaching Party; provided that if such material breach is incapable of cure, then the notifying Party may terminate this Agreement by notice effective at the expiration of such thirty (30)-day cure period. Either Party shall have the right to terminate this Agreement by notice to the other Party with immediate effect if such other Party fails to perform any of its obligations under Section 13.4 (Anti-Corruption) or breaches any representation or warranty contained in Section 13.4 (Anti-Corruption). In addition: (i) this Agreement may be terminated by the non-breaching party for material breach of any other Clinical Trial Collaboration and Supply Agreement between the Parties (or their Affiliates) involving MSD Compound if such material breach occurred or was discovered during the Term and such material breach is not cured in accordance with the terms of such other Clinical Trial Collaboration and Supply Agreement; and (ii) in the event this Agreement is terminated pursuant to this Section 6.3, the terminating Party will have the right to terminate any or all other Clinical Trial Collaboration and Supply Agreements between the Parties by written notice given within thirty (30) days after termination of this Agreement becomes effective pursuant to this Section 6.3.

6.4.

Termination for Patient Safety. If either Party determines in good faith that the MSD Compound Study or Collaborator Clinical Trial may unreasonably adversely affect patient safety, such Party shall promptly notify the other Party of such determination. The Party receiving such notice may propose modifications to the MSD Compound Study or Collaborator Clinical Trial to address the safety issue identified by the other Party and, if the notifying Party agrees, shall act to immediately implement such modifications; provided, however, that if the notifying Party, in its sole discretion, believes that there is imminent danger to patients, such Party need not wait for the proposed modifications and may instead terminate this Agreement immediately by notice to the other Party with immediate effect. Furthermore, the notifying Party may terminate this Agreement by notice to the other Party with immediate effect if, in its sole discretion, it believes that the modifications proposed by the other Party will not resolve the patient safety issue.

6.5.

Termination for Regulatory Action; Other Reasons. Either Party may terminate this Agreement by notice to the other Party with immediate effect in the event that any Regulatory Authority takes any action, or raises any objection, that prevents the terminating Party from supplying its Compound for purposes of the MSD Compound Study. Additionally, either Party shall have the right to terminate this Agreement by notice with immediate effect to the other Party in the event that it determines in its sole discretion to withdraw any applicable Regulatory Approval for its Compound or to discontinue development of its Compound for medical, scientific or legal reasons.

6.6.

Return of MSD Compound. If Collaborator remains in possession (including through any Affiliate or Subcontractor) of MSD Compound at the time this Agreement expires or is terminated, Collaborator shall promptly return or destroy all unused MSD Compound as instructed by MSD in its sole discretion. Collaborator shall provide certification of any requested destruction.

6.7.

Survival. The provisions of Sections 2.9 (Subsequent Study), 3.4 (Debarred Personnel; Exclusions Lists) through 3.10 (Regulatory Submission)(inclusive), 6.7 (Survival) through 6.10 (Manufacturing Costs)(inclusive), 8.5 (Provision of Compounds), 8.11 (Quality Control), 8.12 (VAT), 12.2 (Publication), 13.4.6, 14.2 (Indemnification), and 14.3 (LIMITATION OF LIABILITY), and Articles 1 (DEFINITIONS), 5 (ADVERSE EVENT REPORTING), 9 (CONFIDENTIALITY) through 12 (PUBLICATIONS; PRESS RELEASES)(inclusive), 17 (ENTIRE AGREEMENT; AMENDMENT; WAIVER), and 20 (INVALID PROVISION) through 25 (CONSTRUCTION) (inclusive) shall survive the expiration or termination of this Agreement.

6.8.

No Prejudice. Termination of this Agreement shall be without prejudice to any claim or right of action of either Party for any breach of this Agreement. Except as set forth in Section 6.10 (Manufacturing Costs) and the foregoing sentence, the non-terminating Party shall have no claim against the terminating Party for compensation for any loss of whatever nature by virtue of the termination of this Agreement.

6.9.

Confidential Information. Upon expiration or termination of this Agreement, each Party and its Affiliates shall promptly return to the Disclosing Party or destroy any Confidential Information of the Disclosing Party (other than Clinical Data, Sample Testing Results and Inventions) furnished to the Receiving Party; provided, however that the Receiving Party may retain one copy of such Confidential Information in its confidential files, solely for purposes of exercising the Receiving Party’s rights hereunder, satisfying its obligations hereunder or complying with any legal proceeding or requirement with respect thereto, and provided further that the Receiving Party shall not be required to erase electronic files created in the ordinary course of business during automatic system back-up procedures pursuant to its electronic record retention and destruction practices that apply to its own general electronic files and information so long as such electronic files are: (i) maintained only on centralized storage servers (and not on personal computers or devices); (ii) not accessible by any of its personnel (other than its information technology specialists); and (iii) not otherwise accessed subsequently except with the written consent of the Disclosing Party or as required by law or legal process. Such retained copies of Confidential Information shall remain subject to the confidentiality and non-use obligations herein.

6.10.

Manufacturing Costs. In the event of termination by MSD pursuant to Section 6.2 (MSD Termination for Unsafe Use) or 6.3 (Termination for Breach), MSD shall be entitled to reimbursement by Collaborator for the applicable pro-forma invoice value per Kit. The total aggregate amount of reimbursement under this Section 6.10 shall not exceed two hundred fifty thousand US Dollars ($250,000) if the number of subjects is less than seventy-five (75), five hundred thousand US Dollars ($500,000) if the number of subjects is seventy-five (75) or more but less than one hundred and fifty (150), seven hundred fifty thousand US Dollars ($750,000) if the number of subjects is one hundred and fifty (150) or more but less than two hundred and twenty-five (225) and so on.

COSTS.

Each Party will be responsible for its own internal costs and expenses to support the Collaborator Clinical Trial, including: (i) the provision of its Compound in accordance with this Agreement (including all Manufacturing, acceptance and release testing) and the costs of any Sample Testing conducted by such Party. For the avoidance of doubt, Collaborator will not be required to reimburse MSD for any costs or expenses incurred by MSD or its Affiliates in connection with the MSD Compound Study (except as provided in Section 6.10 (Manufacturing Costs) or 8.9.2.2) and MSD will not be required to reimburse Collaborator for any costs or expenses incurred by Collaborator or its Affiliates in connection with the Collaborator Clinical Trial.

SUPPLY AND USE OF COMPOUNDS.

8.1.

Supply of the Compounds. Subject to the terms and conditions of this Agreement, each of Collaborator and MSD will use commercially-reasonable efforts to supply, or cause to be supplied, its Compound in the quantities and on the timelines set forth in Exhibit B, for use in the MSD Compound Study. If a change to the Protocol in accordance with Article 4 (PROTOCOL AND INFORMED CONSENTS; CERTAIN COVENANTS) requires an increase of the quantity of MSD Compound to be provided of more than twenty percent (20%), the Parties shall amend Exhibit B to reflect such changes. Each Party shall also provide the other Party a contact person for the supply of its Compound under this Agreement. Notwithstanding the foregoing, or anything to the contrary herein, if a Party is: (i) not supplying its Compound in accordance with the terms of this Agreement, then the other Party shall have no obligation to supply its Compound; or (ii) allocating under Section 8.10 (Shortage; Allocation), then the other Party may allocate proportionally.

8.2.

Manufacturing Delay. Each Party shall notify the other Party as promptly as possible in the event of any Manufacturing delay that is likely to adversely affect supply of its Compound hereunder.

8.3.

Compound Commitments. Each Party agrees, at its own cost, to Manufacture and supply its Compound in accordance with this Agreement and the Related Agreements. Without limiting the foregoing, each Party is responsible for obtaining all regulatory approvals (including facility licenses) that are required to Manufacture its Compound in accordance with Applicable Law (provided that Collaborator shall be responsible for obtaining Regulatory Approvals for the MSD Compound Study as set forth in Section 3.5 (Regulatory Matters)).

8.4.

Minimum Shelf Life Requirements. Each Party shall use commercially reasonable efforts to supply its Compound hereunder with an adequate remaining shelf life at the time of Delivery to meet the MSD Compound Study requirements.

8.5.

Provision of Compounds.

8.5.1.

MSD will Deliver the MSD Compound to the location specified by Collaborator. Title for the MSD Compound shall transfer from MSD to Collaborator at Delivery. All costs associated with the subsequent transportation, warehousing and distribution of MSD Compound shall be borne by Collaborator. Collaborator will, or will cause its designee to: (i) take Delivery of the MSD Compound supplied hereunder; (ii) perform the acceptance (including testing) procedures allocated to it under the Clinical Quality Agreement; (iii) subsequently label and package the MSD Compound (in accordance with Section 8.6 (Labeling and Packaging; Use, Handling and Storage)); and promptly ship the MSD Compound to the MSD Compound Study sites for use in the MSD Compound Study, in compliance with Applicable Law and the Clinical Quality Agreement; (iv) keep complete and accurate records pertaining to the use and disposition of MSD Compound, including records relating to its storage, shipping (cold chain), in-transport temperature recorder(s), receipt verification, chain-of-custody activities and usage and inventory reconciliation; (v) make the records described in subsection (iv) and such other documentation as may be reasonably requested by MSD available for review by MSD for the purpose of conducting investigations for the determination of MSD Compound safety or efficacy and Collaborator’s compliance with this Agreement with respect to the MSD Compound.

8.5.2.

Collaborator is solely responsible for supplying (including all Manufacturing, acceptance and release testing) the Collaborator Compound for the Collaborator Clinical Trial and the subsequent handling, storage, transportation, warehousing and distribution of all such Collaborator Compound. Collaborator shall ensure that all such activities are conducted in compliance with Applicable Law and, with respect to the MSD Compound Study, the Clinical Quality Agreement.

8.6.

Labeling and Packaging; Use, Handling and Storage.

8.6.1.

The Parties’ obligations with respect to the labeling and packaging of the MSD Compound are as set forth in the Clinical Quality Agreement. MSD shall provide the MSD Compound to Collaborator in the form of unlabeled vials, and Collaborator shall label, package, use, store, transport, handle and dispose of the MSD Compound in accordance with MSD’s instructions and the terms and conditions of the Clinical Quality Agreement and Applicable Law.

8.6.2.

Collaborator shall: (i) use the MSD Compound solely for purposes of performing the MSD Compound Study; and (ii) not use the MSD Compound in any manner that is inconsistent with this Agreement or for any commercial purpose. Collaborator shall not reverse engineer, reverse compile, disassemble or otherwise attempt to derive the composition or underlying information, structure or ideas of the MSD Compound, and in particular shall not analyze the MSD Compound by physical, chemical or biochemical means except as necessary to perform its obligations under the Clinical Quality Agreement.

8.7.

Product Specifications. A certificate of analysis shall accompany each shipment of the MSD Compound to Collaborator. Upon request, Collaborator shall provide MSD with a certificate of analysis covering each shipment of Collaborator Compound used in the MSD Compound Study.

8.8.

Changes to Manufacturing. Each Party may make changes from time to time to its Compound or the Manufacturing Site, provided that such changes shall be in accordance with the Clinical Quality Agreement.

8.9.

Product Testing; Nonconformance.

8.9.1.

After Manufacturer’s Release. After Manufacturer’s Release of the MSD Compound and concurrently with Delivery of the Compound to Collaborator, MSD shall provide Collaborator with the documentation described in the Clinical Quality Agreement. Collaborator shall conduct the acceptance procedures under the Clinical Quality Agreement within the time frames set forth therein. Collaborator shall be solely responsible for taking all steps necessary to determine that MSD Compound or Collaborator Compound, as applicable, is suitable for release before making such Compounds available for human use, and MSD shall assist Collaborator as Collaborator reasonably requests in making such determination for the MSD Compound. Collaborator shall be responsible for storage and maintenance of the MSD Compound until it is tested and released, which storage and maintenance shall be in compliance with: (i) the Specifications for the MSD Compound, (ii) the Clinical Quality Agreement, (iii) Applicable Law, and (iv) any specific storage and maintenance requirements as may be provided by MSD from time to time. Collaborator shall be responsible for any failure of the MSD Compound to meet the Specifications to the extent caused after Delivery to Collaborator hereunder.

8.9.2.

Non-Conformance.

8.9.2.1.

In the event that either Party becomes aware that any Compound may have a Non-Conformance, despite testing and quality assurance activities (including any activities conducted by the Parties under Section 8.9.1 (After Manufacturer’s Release)), such Party shall immediately notify the other Party. Notification related to MSD Compound shall be in accordance with the Clinical Quality Agreement. MSD shall investigate any Non-Conformance of the MSD Compound in accordance with the Clinical Quality Agreement.

8.9.2.2.

In the event that all or any portion of any proposed or actual shipment of the MSD Compound is agreed to be Non-Conforming at the time of Delivery to Collaborator then MSD shall replace any such Non-Conforming MSD Compound that has not been administered. The sole and exclusive remedies of Collaborator with respect to any MSD Compound that is found to be Non- Conforming at the time of Delivery shall be: (i) replacement of such MSD Compound as set forth in this Section 8.9.2.2; (ii) indemnification in accordance with Section 14.2 (Indemnification) (if applicable); or (iii) termination of this Agreement in accordance with Section 6.3 (Termination for Breach) (if applicable). In the event MSD Compound is lost or damaged by Collaborator after Delivery, MSD shall provide additional MSD Compound (when available) to Collaborator; provided that Collaborator shall reimburse MSD for the applicable pro-forma invoice value per Kit. The total aggregate amount of reimbursement under this Section 8.9.2.2 shall not exceed two hundred fifty thousand US Dollars ($250,000) if the number of subjects is less than seventy- five (75), five hundred thousand US Dollars ($500,000) if the number of subjects is seventy-five (75) or more but less than one hundred and fifty (150), seven hundred fifty thousand US Dollars ($750,000) if the number of subjects is one hundred and fifty (150) or more but less than two hundred and twenty-five (225) and so on.

MSD shall have no obligation to provide additional MSD Compound more than once. Except as set forth in this Section 8.9.2.2, MSD shall have no obligation replace any MSD ▇▇▇▇▇▇▇▇ supplied hereunder.

8.9.2.3.

Collaborator shall be responsible for, and MSD shall have no obligation or liability with respect to, any Collaborator Compound that is found to have a Non-Conformance. Collaborator shall replace any such Collaborator Compound that has not been administered. The sole and exclusive remedies of MSD with respect to any Collaborator Compound that is found to have a Non-Conformance at the time of Delivery shall be: (i) replacement of such Collaborator Compound as set forth in this Section 8.9.2.3; (ii) indemnification in accordance with Section 14.2 (Indemnification) (if applicable); and (iii) termination of this Agreement in accordance with Section 6.3 (Termination for Breach) (if applicable).

8.9.3.

Resolution of Discrepancies. Disagreements regarding any determination of Non- Conformance by Collaborator shall be resolved in accordance with this Clinical Quality Agreement or, in situations where the Clinical Quality Agreement does not apply, Section 21 (GOVERNING LAW; DISPUTE RESOLUTION) of this Agreement.

8.10.

Shortage; Allocation. If a Party believes in good faith that it will not be able to fulfill its supply obligations hereunder because its Compound is in short supply, such Party will provide prompt written notice to the other Party of such shortage, the shipments of Compound hereunder expected to be impacted and the quantity of its Compound that such Party reasonably determines it will be able to supply and the Parties will promptly discuss the situation (including allocation of Compound supplied hereunder within the MSD Compound Study). The Party experiencing the shortage shall have sole discretion, subject to Applicable Law, to determine how much Compound it will supply during the shortage, and such Party shall not be deemed to be in breach of this Agreement for failure to supply any quantities of its Compound as a result of such shortage. In case of one Party’s shortage of its Compound, the other Party shall be relieved of its obligations under this Agreement to the extent impacted by such shortage.

8.11.

Quality Control. Each Party shall implement and perform operating procedures and controls for sampling, stability and other testing of its Compound, and for validation, documentation and release of its Compound and such other quality-assurance and quality-control procedures as are required by the Specifications, cGMPs and (with respect only to the MSD Compound) the Clinical Quality Agreement.

8.12.

VAT. Where MSD is treated as making a supply of goods in a particular jurisdiction for no consideration for VAT purposes, and Collaborator is treated as receiving such supply in the same jurisdiction, thus resulting in an amount of VAT being properly chargeable on such supply, Collaborator shall be obliged to pay to MSD the amount of VAT properly chargeable on such supply. Collaborator shall pay such VAT to MSD on receipt of a valid VAT invoice from MSD issued in accordance with the laws and regulations of the jurisdiction in which the VAT is properly chargeable. MSD will: (i) determine, in accordance with Applicable Law, the value of the supply that has been made and, as a result, the corresponding amount of VAT that is properly chargeable; and (ii) provide Collaborator any information or copies of documents in MSD’s Control as are reasonably necessary for VAT purposes to evidence that such supply will take, or has taken, place in the same jurisdiction.

CONFIDENTIALITY.

9.1.

Confidential Information. Subject to Section 13.4.8, Collaborator and MSD agree to hold in confidence all Confidential Information of the other Party and use such Confidential Information only to fulfill its obligations or exercise its rights hereunder. Without limiting the foregoing, the Receiving Party may not, without the prior written permission of the Disclosing Party, disclose any Confidential Information of the Disclosing Party to any Third Party except to the extent such disclosure is: (i) required by Applicable Law; (ii) pursuant to the terms of this Agreement; or (iii) necessary for the conduct of the MSD Compound Study, and in each case (i) through (iii) provided that the Receiving Party shall provide reasonable advance notice to the Disclosing Party before making such disclosure. For the avoidance of doubt, Collaborator may, without MSD’s consent, disclose Confidential Information to clinical trial sites and clinical trial investigators performing the MSD Compound Study, the data safety monitoring and advisory boards relating to the MSD Compound Study, and Regulatory Authorities working with Collaborator on the MSD Compound Study, in each case as necessary for the performance of the MSD Compound Study and provided that such Persons (other than governmental entities) are bound by an obligation of confidentiality at least as stringent as the obligations contained herein.

9.2.

Inventions. Notwithstanding the foregoing: (i) Inventions that constitute Confidential Information and are jointly owned by the Parties shall constitute the Confidential Information of both Parties and each Party shall have the right to use and disclose such Confidential Information in accordance with Articles 10 (INTELLECTUAL PROPERTY), 11 (REPRINTS; RIGHTS OF CROSS-REFERENCE) and 12 (PUBLICATIONS; PRESS RELEASES); and (ii) Inventions that constitute Confidential Information and are solely owned by one Party shall constitute the Confidential Information of that Party and such Party shall have the right to use and disclose such Confidential Information in accordance with Articles 10 (INTELLECTUAL PROPERTY), 11 (REPRINTS; REFERENCES IN PUBLICATION) and 12 (PUBLICATIONS; PRESS RELEASES).

9.3.

Personal Identifiable Data. All Confidential Information containing personal identifiable data shall be handled in accordance with all applicable data-protection and privacy laws, rules and regulations.

9.4.

Publicity/Use of Names. Except as set forth in Section 12.3 (Press Releases), no disclosure of the existence or terms of this Agreement may be made by either Party, and no Party shall use the name, trademark, trade name or logo of the other Party, its Affiliates or their respective employee(s) in any publicity, promotion, news release or disclosure relating to this Agreement or its subject matter without the prior express written permission of such Person, except as may be required by Applicable Law.

10.

INTELLECTUAL PROPERTY.

10.1.

Joint Ownership. Collaborator and MSDIG shall jointly own all rights to all Joint Inventions and any Joint Patent claiming such Joint Invention(s). Collaborator hereby assigns to MSDIG an undivided interest in, to and under all Joint Inventions that are invented or created solely by Collaborator or by Persons having an obligation to assign such rights to Collaborator. MSD hereby assigns to Collaborator an undivided interest in, to and under all Joint Inventions that are invented or created solely by MSD or Persons having an obligation to assign such rights to MSD. For those countries where a specific license is required for a joint owner of a Joint Invention to exploit such Joint Invention in such countries: Each of MSD and Collaborator hereby grants the other Party a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid-up license, transferable and sublicensable, under the granting Party’s right, title and interest in and to all Joint Inventions to exploit such Inventions in accordance with the terms of this Agreement. For clarity, the terms of this Agreement do not provide either Party with any right, title or interest or any license to the other Party’s intellectual property except as necessary to conduct the MSD Compound Study and as expressly provided under this Agreement, including as set forth in Section 10.8 (Mutual Freedom to Operate).

10.2.

Right to Exploit. Each Party shall have the right to freely exploit Joint Inventions within and outside the MSD Compound Study, without any obligation or accounting to the other Party; provided, however, that MSD may not exploit any granted Joint Patents, directly or indirectly, to research, develop or commercialize a Collaborator Class Compound (except for the Collaborator Compound in Combination with the MSD Compound as permitted under this Agreement), and Collaborator may not exploit any granted Joint Patents, directly or indirectly, to research, develop or commercialize a PD-1 Antagonist (except for the MSD Compound in Combination with the Collaborator Compound as permitted under this Agreement).

10.3.

Prosecution. As necessary following the Effective Date, but in any event as soon as practicable after the discovery of a Joint Invention, patent representatives of the Parties shall meet (in person or by telephone) to discuss the patenting strategy for any Joint Inventions that may arise. In particular, the Parties shall discuss which Party will file a Joint Patent or whether outside counsel will file any such Joint Patent. Unless otherwise agreed, the Parties shall appoint mutually acceptable outside counsel to prosecute and maintain any Joint Patents. In any event, the Parties shall consult and reasonably cooperate with one another in the preparation, filing, prosecution (including prosecution strategy) and maintenance of each Joint Patent and shall equally share the expenses associated with any Joint Patents. Unless otherwise agreed, the scope of the claim(s) of any Joint Patent shall be limited to combinations of: (i) the MSD Compound or variants thereof comprising the same complementarity-determining regions as the MSD Compound; and (ii) if the Collaborator Compound is a compound that is not an antibody, the Collaborator Compound and if the Collaborator Compound is an antibody, the Collaborator Compound or any variants thereof comprising the same complementarity- determining regions as the Collaborator Compound.

10.4.

Declining to File, Prosecute or Maintain. In the event the Pursuing Party wishes to file a Joint Patent in respect of a Joint Invention and the Non-Pursuing Party does not want to file such Joint Patent or does not want to file in a particular country, the Pursuing Party will have the right to file, prosecute, and maintain such Joint Patent in any countries where it wants to do so and the Non-Pursuing Party does not. If the Opting-out Party wishes to discontinue the prosecution and maintenance (or the sharing of costs with respect thereto) of a Joint Patent (in one or more countries), the Continuing Party, at its sole option, may continue such prosecution and maintenance. The Non-Pursuing Party or Opting-out Party, as the case may be, shall timely execute an assignment of the Joint Invention or Joint Patent to the Pursuing Party or Continuing Party, respectively, and any additional documents as may be reasonably necessary to allow the Pursuing Party or Continuing Party to pursue such filing, prosecution or maintenance in the relevant countries, in each case at the Pursuing Party’s or Continuing Party’s expense. Any Joint Invention or Joint Patent so assigned shall thereafter be owned solely by the Pursuing Party or Continuing Party, shall no longer be considered jointly owned, and the Non- Pursuing Party or Opting-out Party shall have no right to practice under such Joint Patent in the applicable countries. The Pursuing Party or Continuing Party shall be solely responsible for all expenses associated with any such assigned Joint Invention or Joint Patent.

10.5.

Prohibition of Patenting. Except as expressly provided in Section 10.3 (Prosecution) and in furtherance and not in limitation of Section 9.1 (Confidential Information), each Party agrees not to file or prosecute a Patent based on the other Party’s Confidential Information, and to give no assistance to any Third Party for such Patent, in each case without the other Party’s prior written consent.

10.6.

Patent Enforcement.

10.6.1.

Each Party shall promptly notify the other of any Third-Party Infringement of which such Party becomes aware.

10.6.2.

Collaborator shall have the first right to initiate legal action to enforce all Joint Patents and Joint Inventions against Third-Party Infringement resulting from making, having made, importing, using, selling, or offering for sale a product that includes a Collaborator Class Compound but not a PD-1 Antagonist or to defend any declaratory judgment action relating thereto, at its sole expense. In the event that Collaborator fails to initiate or defend such action by the earlier of: (i) ninety (90) days after first being notified or made aware of such Third-Party Infringement; and (ii) thirty (30) days before the expiration date for initiating or defending such action, MSD shall have the right to initiate or defend such action at its sole expense.

10.6.3.

MSD shall have the first right to initiate legal action to enforce all Joint Patents and Joint Inventions against Third-Party Infringement resulting from making, having made, importing, using, selling, or offering for sale a product that includes a PD-1 Antagonist but not a Collaborator Class Compound or to defend any declaratory judgment action relating thereto, at its sole expense. In the event that MSD fails to initiate or defend such action by the earlier of: (i) ninety (90) days after first being notified or made aware of such Third-Party Infringement; and (ii) thirty (30) days before the expiration date for initiating or defending such action, Collaborator shall have the right to do so at its sole expense.

10.6.4.

The Parties shall cooperate to jointly control legal action to enforce all Joint Patents and Joint Inventions against any Third-Party Infringement where such Third-Party Infringement results from the development or sale of a product that includes both a PD-1 Antagonist and a Collaborator Class Compound or to defend any declaratory judgment action relating thereto, and shall share the costs and expenses of such actions equally. Notwithstanding the foregoing, either Party shall have the right to opt-out of controlling such legal action by providing written notice to the other Party by the earliest of: (i) ninety (90) days after first being noticed of such Third-Party Infringement; (ii) thirty (30) days before the expiration date for filing such action; (iii) thirty (30) days before the expiration date for filing an answer to a complaint in a declaratory judgment action; and (iv) fifteen (15) days after notice is received, by one Party from other Party, informing such receiving Party that an application has been filed with the U.S. Food & Drug Administration under Section 351(k) of the U.S. Public Health Services Act (42 U.S.C. 262(k)) seeking approval of a biosimilar or interchangeable biological product of the MSD Compound (when MSD is notifying party) or the Collaborator Compound (if Collaborator Compound is a biological product and Collaborator is notifying Party), whichever comes first.

10.6.5.

If one Party brings any prosecution or enforcement action or proceeding against a Third Party with respect to any Joint Patent, the other Party agrees to be joined as a party plaintiff if requested and to give the first Party reasonable assistance and authority to file and prosecute the suit. The Party bringing suit shall bear its own costs and expenses, and any damages or other monetary awards recovered shall be shared as follows: (i) the amount of such recovery actually received by the Party controlling such action shall be first applied to the out-of-pocket costs of each Party in connection with such action; and then (ii) any remaining proceeds shall be shared by the Parties in proportion to their relative contributions to the total costs and expenses of the litigation, including, as applicable, any costs and expenses of a Party to enforce any Collaborator Background Patents or MSD Background Patents. A settlement or consent judgment or other voluntary final disposition of a suit under this Section 10.6.5 shall not be entered into without the consent of the Party not bringing the suit.

10.7.

Inventions Owned by Each Party. Notwithstanding anything to the contrary contained in Section 10.1 (Joint Ownership), the Parties agree that all rights to Collaborator Inventions shall be the exclusive property of Collaborator and all rights to MSD Inventions shall be the exclusive property of MSD. Each Party shall: (i) be entitled to file and prosecute in its own name applications for Patents in respect of Inventions it owns; and (ii) own Patents that issue from any such applications. For the avoidance of doubt: (a) any Invention generically encompassing the Collaborator Compound or another Collaborator Class Compound (and not the MSD Compound) within its scope, even where the Collaborator Compound or Collaborator Class Compound is not disclosed per se, is a Collaborator Invention; and (b) any Invention generically encompassing the MSD Compound or another PD-1 Antagonist (and not the Collaborator Compound) within its scope, even where the MSD Compound or other PD-1 Antagonist is not disclosed per se, is an MSD Invention. MSD hereby assigns its right, title and interest to any and all Collaborator Inventions to Collaborator, and Collaborator hereby assigns its right, title and interest to any and all MSD Inventions to MSD.

10.8.

Mutual Freedom to Operate. Each Party hereby grants to the other Party a non-exclusive, worldwide, royalty-free, fully paid-up, transferable and sublicensable license to the Collaborator Background Patents (with respect to the grant by Collaborator) and the MSD Background Patents (with respect to the grant by MSD) solely for the purposes of: (a) conducting the MSD Compound Study; (b) researching and developing the Combination in the same indication as the Combination Arm during the Term pursuant to this Agreement; and (c) obtaining and promoting an initial or an updated label indication for the Combination in the same indication as the Combination Arm during the longer of the Term and the life of such Patents; provided, however, that in no event shall: (i) MSD have the right to exploit Collaborator Background Patents to sell any Collaborator Class Compound, either alone or as part of a combination (including the Combination); or (ii) Collaborator have the right to exploit MSD Background Patents to sell any PD-1 Antagonist, either alone or as part of a combination (including the Combination). For clarity, the terms of this Section 10.8 (Mutual Freedom to Operate) do not provide either Party with any rights, title or interest or any license to the Collaborator Background Patents, or the MSD Background Patents except as expressly set forth in the previous sentence.

10.9.

Termination. Any and all licenses granted under Section 10.8 (Mutual Freedom to Operate) shall terminate upon the expiration or earlier termination of this Agreement and shall not survive such expiration or termination; provided, however that the license granted in subsection (c) of Section 10.8 (Mutual Freedom to Operate) shall survive such expiration or termination except that if a Party terminates the Agreement pursuant to Section 6.3 (Termination for Breach), then only the grant to the terminating Party from the non-terminating Party shall survive.

10.10.

Ownership of Other Inventions. Ownership of all Inventions other than Joint Inventions, MSD Inventions and Collaborator Inventions shall be based on inventorship as determined under United States patent law.

11.

REPRINTS; REFERENCES IN PUBLICATION.

Consistent with Applicable Law (including copyright law), each Party may use, refer to, and disseminate reprints of scientific, medical and other published articles and materials from journals, conferences or symposia relating to the MSD Compound Study that disclose the name of a Party, provided, however, that such use does not constitute an endorsement of any commercial product or service by the other Party.

12.

PUBLICATIONS; PRESS RELEASES.

12.1.

Clinical Trial Registry. Collaborator shall register the MSD Compound Study and Collaborator Clinical Trial with the clinical trials registry located at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇, shall list MSD as a collaborator with respect to the Collaborator Clinical Trial, and shall timely publish the results following completion of the MSD Compound Study, after taking appropriate action to secure any intellectual property rights arising from the MSD Compound Study. The results of the MSD Compound Study will be published in accordance with the Protocol.

12.2.

Publication. Each Party shall use reasonable efforts to publish or present scientific papers with respect to the MSD Compound Study in accordance with accepted scientific practice. The Parties agree that, prior to submission of the results of the MSD Compound Study for publication or presentation or any other dissemination of such results (including oral dissemination), the publishing Party shall invite the other to comment on the content of the material to be published, presented, or otherwise disseminated according to the following procedure:

12.2.1.

At least forty-five (45) days prior to submission for publication of any paper, letter or any other publication, or thirty (30) days prior to submission for presentation of any abstract, poster, talk or any other presentation, the publishing Party shall provide to the other Party the full details of the proposed publication, presentation, or dissemination in an electronic version as an email attachment. Upon written request from the other Party, the publishing Party agrees not to submit data for publication/presentation/dissemination for an additional sixty (60) days to allow for actions to be taken to preserve rights for patent protection.

12.2.2.

The publishing Party shall reasonably consider any request by the other Party made within the periods set forth in Section 12.2.1 to modify the publication and the Parties shall work together to timely resolve any issue regarding the content for publication. Notwithstanding the foregoing, MSD Clinical Data shall be subject to final review and approval by MSD, not to be unreasonably withheld.

12.2.3.

The publishing Party shall remove all Confidential Information of the other Party before finalizing the publication.

12.3.

Press Releases. Unless otherwise required by Applicable Law, neither Party shall make any public announcement concerning this Agreement without the prior written consent of the other Party. To the extent a Party desires to make such public announcement, such Party shall request permission of the other Party and provide the other Party with a draft thereof for review and comment at least ten (10) Business Days prior to the date on which such Party would like to make the public announcement.

13.

REPRESENTATIONS AND WARRANTIES; DISCLAIMERS.

13.1.

Due Authorization. Each of Collaborator and MSD represents and warrants to the other that: (i) it has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder; (ii) it has taken all necessary corporate action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; and (iii) this Agreement has been duly executed and delivered on behalf of such Party and constitutes a legal, valid and binding obligation of such Party that is enforceable against it in accordance with its terms.

13.2.

Compounds.

13.2.1.

Collaborator Compound. Collaborator hereby represents and warrants to MSD that: (i) Collaborator has the full right, power and authority to grant all of the licenses granted to MSD under this Agreement; (ii) Collaborator Controls the Collaborator Compound; and (iii) at the time of Delivery of the Collaborator Compound, such Collaborator Compound shall have been Manufactured and supplied in compliance with its Specifications and all Applicable Law.

13.2.2.

MSD Compound. MSD hereby represents and warrants to Collaborator that: (i) MSD has the full right, power and authority to grant all of the licenses granted to Collaborator under this Agreement; (ii) MSD Controls the MSD Compound; and (iii) at the time of Delivery of the MSD Compound, such MSD Compound shall have been Manufactured and supplied in compliance with its Specifications, the Clinical Quality Agreement, and all Applicable Law.

13.3.

Results. Neither Party undertakes that the MSD Compound Study shall lead to any particular result, nor is the success of the MSD Compound Study guaranteed. Neither Party shall be liable for any use that the other Party may make of the Joint Clinical Data or shared Sample Testing Results, nor for advice or information given in connection therewith.

13.4.

Anti-Corruption.

13.4.1.

The Parties acknowledge that the corporate policies or Codes of Conduct of Collaborator and MSD and their respective Affiliates require that each Party’s business be conducted within the letter and spirit of the law. Each Party agrees to conduct the business contemplated herein in a manner that is consistent with all Applicable Law, including the FCPA.

13.4.2.

Each Party represents and warrants that it and its Related Entities have not, and covenants that it and its Related Entities will not, in connection with the performance of this Agreement, directly or indirectly, make, promise, authorize, ratify or offer to make, or take any action in furtherance of, any payment or transfer of anything of value for the purpose of influencing, inducing or rewarding any act, omission or decision to secure an improper advantage; or improperly assisting it in obtaining or retaining business for it or the other Party, or in any way with the purpose or effect of public or commercial bribery.

13.4.3.

Neither Party shall contact, or otherwise knowingly meet with, any Government Official for the purpose of discussing activities arising out of or in connection with this Agreement without the prior written approval of the other Party, except where such meeting is consistent with the purpose and terms of this Agreement and in compliance with Applicable Law.

13.4.4.

Each Party represents and warrants that it: (i) is not excluded, debarred, suspended, proposed for suspension or debarment, in Violation or otherwise ineligible for government programs; (ii) has not employed or subcontracted with any Person for the performance of the MSD Compound Study who is excluded, debarred, suspended, proposed for suspension or debarment, or is in Violation or otherwise ineligible for government programs; and (iii) has conducted anti-corruption and bribery (e.g. FCPA) due-diligence review of all Third Parties it may hire to act on its behalf in connection with its performance under this Agreement.

13.4.5.

Each Party represents and warrants that, except as disclosed to the other in writing prior to the Effective Date, such Party: (i) does not have any interest that directly or indirectly conflicts with its proper and ethical performance of this Agreement; (ii) shall maintain arm’s length relations with all Third Parties with which it deals for or on behalf of the other in performance of this Agreement; and (iii) has provided complete and accurate information and documentation to the other Party, the other Party’s Affiliates and its and their personnel in the course of any due diligence conducted by the other Party for this Agreement, including disclosure of any officers, employees, owners or Persons directly or indirectly retained by such Party in relation to the performance of this Agreement who are Government Officials or relatives of Government Officials. Each Party shall make all further disclosures to the other Party as are necessary to ensure the information provided remains complete and accurate throughout the Term. Subject to the foregoing, each Party agrees that prior to hiring or retaining any Government Official to assist in its performance of this Agreement it shall obtain the written consent of the other Party and complete a satisfactory anti- corruption and bribery (e.g., FCPA) due diligence review of such Government Official consistent with industry standards. Each Party further covenants that any future information and documentation submitted to the other Party as part of further due diligence or a certification shall be complete and accurate.

13.4.6.

Each Party shall have the right during the Term, and for a period of two (2) years following termination of this Agreement, to conduct an investigation and audit of the other Party’s activities, books and records, to the extent they relate to that other Party’s performance under this Agreement, to verify compliance with the terms of this Section 13.4. Such other Party shall cooperate fully with such investigation or audit, the scope, method, nature and duration of which shall be at the sole reasonable discretion of the Party requesting such audit.

13.4.7.

Each Party shall use commercially-reasonable efforts to ensure that all transactions under the Agreement are properly and accurately recorded in all material respects on its books and records and that each document upon which entries in such books and records are based is complete and accurate in all material respects. Each Party further represents, warrants and covenants that all books, records, invoices and other documents relating to payments and expenses under this Agreement are and shall be complete and accurate and reflect in reasonable detail the character and amount of transactions and expenditures. Each Party shall maintain a system of internal accounting controls reasonably designed to ensure that no off-the-books or similar funds or accounts will be maintained or used in connection with this Agreement.

13.4.8.

Each Party agrees that in the event that the other Party believes in good faith that there has been a possible violation of any provision of this Section 13.4, such other Party may make full disclosure of such belief and related information (including, if necessary, Confidential Information) needed to support such belief at any time and for any reason to any competent government bodies and agencies, and to anyone else such Party determines in good faith has a legitimate need to know.

13.4.9.

Each Party shall comply with its own ethical business practices policy and any corporate integrity agreement (if applicable) to which it is subject. Each Party shall ensure that all of its employees involved in performing its obligations under this Agreement are made specifically aware of the compliance requirements under this Section 13.4. In addition, each Party shall ensure that all such employees participate in and complete mandatory compliance training to be conducted by each Party, including specific training on anti-bribery and corruption, prior to their performance of any obligations or activities under this Agreement. Each Party shall certify its continuing compliance with the requirements under this Section 13.4 on a periodic basis during the Term in such form as may be reasonably specified by the other Party.

13.4.10.

Each Party shall have the right to terminate this Agreement immediately in accordance with Section 6.3 (Termination for Breach) in the event of any violation of this Section 13.4 by the other Party.

13.5.

DISCLAIMER. EXCEPT AS EXPRESSLY PROVIDED HEREIN, MSD MAKES NO WARRANTIES, EXPRESS OR IMPLIED WITH RESPECT TO THE MSD COMPOUND, AND COLLABORATOR MAKES NO WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE COLLABORATOR COMPOUND, IN EACH CASE INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

14.

INSURANCE; INDEMNIFICATION; LIMITATION OF LIABILITY.

14.1.

Insurance. Each Party warrants that it maintains a policy or program of insurance or self- insurance at levels sufficient to support the indemnification obligations assumed herein. Upon request, a Party shall provide evidence of such insurance.

14.2.

Indemnification.

14.2.1.

Indemnification by Collaborator. Collaborator agrees to defend, indemnify and hold harmless MSD, its Affiliates, and its and their employees, officers, directors, Subcontractors and agents from and against any Liability, except to the extent that such Liability was directly caused by: (i) negligence or willful misconduct on the part of MSD (or any of its Affiliates, or its and their employees, officers, directors, Subcontractors or agents); (ii) a breach of this Agreement by MSD; or (iii) a violation of Applicable Law by MSD.

14.2.2.

Indemnification by MSD. MSD agrees to defend, indemnify and hold harmless Collaborator, its Affiliates, and its and their employees, officers, directors, Subcontractors and agents from and against any Liability to the extent such Liability was directly caused by: (i) negligence or willful misconduct on the part of MSD (or any of its Affiliates, or its and their employees, officers, directors, Subcontractors or agents); (ii) a breach of this Agreement by MSD; or (iii) a violation of Applicable Law by MSD.

14.2.3.

Procedure. The obligations of MSD and Collaborator under this Section 14.2 (Indemnification) are conditioned upon the delivery of written notice to the indemnifying Party of any potential Liability within a reasonable time after the indemnified Party becomes aware of such potential Liability. The indemnifying Party will have the right to assume the defense of any suit or claim related to the Liability (using counsel reasonably satisfactory to the indemnified Party) if it has assumed responsibility for the suit or claim in writing; provided that the indemnified Party may assume the responsibility for such defense to the extent the indemnifying Party does not do so in a timely manner). The indemnified Party may participate in (but not control) the defense thereof at its sole cost and expense. The Defending Party shall keep the Other Party advised of the status of such action, suit, proceeding or claim and the defense thereof and shall consider recommendations made by the Other Party with respect thereto. The Defending Party shall not agree to any settlement of such action, suit, proceeding or claim without the prior written consent of the Other Party, which shall not be unreasonably withheld, conditioned or delayed. The Defending Party, but solely to the extent the Defending Party is also the indemnifying Party, shall not agree to any settlement of such action, suit, proceeding or claim or consent to any judgment in respect thereof that does not include a complete and unconditional release of the Other Party from all liability with respect thereto or that imposes any liability or obligation on the Other Party without the prior written consent of the Other Party.

14.2.4.

MSD Compound Study Subjects. Neither Party shall offer compensation on behalf of the other Party to any MSD Compound Study subject or bind the other Party to any indemnification obligations in favor of any MSD Compound Study subject.

14.3.

LIMITATION OF LIABILITY. IN NO EVENT SHALL EITHER PARTY, ITS AFFILIATES AND ITS OR THEIR EMPLOYEES DIRECTORS, SUBCONTRACTORS OR AGENTS) BE LIABLE TO THE OTHER PARTY UNDER ANY THEORY FOR, NOR SHALL ANY INDEMNIFIED PARTY HAVE THE RIGHT TO RECOVER, ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR OTHER SIMILAR DAMAGES, ANY PUNITIVE DAMAGES, ANY LOST PROFIT, LOST SALE OR LOST OPPORTUNITY DAMAGES (WHETHER SUCH CLAIMED DAMAGES ARE DIRECT OR INDIRECT), ARISING DIRECTLY OR INDIRECTLY OUT OF OR RELATED TO THIS AGREEMENT, THE ACTIVITIES TO BE CONDUCTED BY THE PARTIES HEREUNDER OR THE COLLABORATOR CLINICAL TRIAL (INCLUDING THE MSD COMPOUND STUDY). SUCH LIMITATION SHALL NOT APPLY TO DAMAGES PAID OR PAYABLE TO A THIRD PARTY BY AN INDEMNIFIED PARTY FOR WHICH IT IS ENTITLED TO INDEMNIFICATION HEREUNDER OR WITH RESPECT TO DAMAGES ARISING OUT OF OR RELATED TO A PARTY’S BREACH OF ITS OBLIGATIONS UNDER THIS AGREEMENT WITH RESPECT TO USE, DISCLOSURE, LICENSE, ASSIGNMENT OR OTHER TRANSFER OF JOINT CLINICAL DATA, CONFIDENTIAL INFORMATION, JOINT INVENTIONS AND SAMPLE TESTING RESULTS.

15.

USE OF NAME.

Except as otherwise provided herein, neither Party shall have any right, express or implied, to use in any manner the name or other designation of the other Party or any other trade name, trademark or logo of the other Party for any purpose in connection with the performance of this Agreement without the other Party’s prior written consent.

16.

FORCE MAJEURE.

If, in the performance of this Agreement, one of the Parties is prevented, hindered or delayed by reason of any cause beyond such Party’s reasonable control (e.g., war, riots, fire, strike, acts of terror, governmental action and governmental laws), such Party shall be excused from performance to the extent that it is necessarily prevented, hindered or delayed. The non-performing Party shall notify the other Party of such any such event within ten (10) days after such occurrence by giving notice to the other Party stating the nature of the event, its anticipated duration, and any action being taken to avoid or minimize its effect. The suspension of performance will be of no greater scope and no longer duration than is necessary and the non-performing Party shall use commercially reasonable efforts to remedy its inability to perform.

17.

ENTIRE AGREEMENT; AMENDMENT; WAIVER.

This Agreement, together with the Appendices, Exhibits and Schedules hereto and the Related Agreements, constitutes the sole, full and complete agreement by and between the Parties with respect to the subject matter of this Agreement, and all prior agreements, understandings, promises and representations, whether written or oral, with respect thereto are superseded by this Agreement. In the event of a conflict between a Related Agreement and this Agreement, the terms of this Agreement shall control except: (i) in the event of any inconsistencies between the terms of this Agreement and the Data Protection Terms, the Data Protection Terms shall control; (ii) in the event of any inconsistency between the terms of this Agreement and the Pharmacovigilance Agreement that relate directly to the pharmacovigilance responsibilities of the Parties (including the exchange of safety data), the terms of the Pharmacovigilance Agreement shall control. No amendments, changes, additions, deletions or modifications to or of this Agreement shall be valid unless reduced to writing and signed by the Parties hereto. Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition. The waiver by either Party of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by said other Party whether of a similar nature or otherwise.

18.

ASSIGNMENT AND AFFILIATES.

Neither Party shall assign or transfer this Agreement without the prior written consent of the other Party; provided, however, that either Party may assign all or any part of this Agreement without the other Party’s consent: (i) to one or more of its Affiliates, and any and all rights and obligations of either Party may be exercised or performed by its Affiliates, provided in each case, that such Affiliates agree to be bound by this Agreement; or (ii) in connection with the sale of all or substantially all of its assets to which this Agreement relates, whether by merger, acquisition or similar transaction or series of related transactions. This Agreement shall be binding upon the successors and permitted assigns of the Parties and the name of a Party appearing herein shall be deemed to include the names of such Party’s successors and permitted assigns to the extent necessary to carry out the intent of the Agreement. Any assignment not in accordance with this Article 18 shall be null, void and of no legal effect.

19.

CHANGE OF CONTROL.

If Collaborator undergoes a Change of Control in which the acquiring party owns or controls a competing PD-1 Antagonist, then upon MSD’s request, the Parties and the acquiring party shall engage in discussion and shall adopt reasonable procedures to be agreed with MSD to prevent the disclosure of Sensitive Information beyond Collaborator’s personnel having access to or knowledge of Sensitive Information prior to the Change of Control and other personnel of the acquiring party approved by MSD, and to control the dissemination of Sensitive Information disclosed after the Change of Control to prevent the use of Sensitive Information for the development or commercialization of competing PD-1 Antagonist products.

20.

INVALID PROVISION.

If any provision of this Agreement is held to be illegal, invalid or unenforceable, the remaining provisions shall remain in full force and effect and will not be affected by the illegal, invalid or unenforceable provision. In lieu of the illegal, invalid or unenforceable provision, the Parties shall negotiate to agree upon a reasonable provision that is legal, valid and enforceable to carry out as nearly as practicable the original intention of the entire Agreement.

21.

GOVERNING LAW; DISPUTE RESOLUTION.

21.1.

The Parties shall attempt to settle all disputes arising out of or in connection with this Agreement in an amicable manner. Any claim, dispute or controversy arising out of or relating to this Agreement, including the breach, termination or validity hereof or thereof, shall be governed by and construed in accordance with the substantive laws of the State of New York, without giving effect to its choice of law principles.

21.2.

Nothing contained in this Agreement shall deny either Party the right to seek injunctive or other equitable relief from a court of competent jurisdiction in the context of a bona fide emergency or prospective irreparable harm, and such an action may be filed or maintained notwithstanding any ongoing discussions between the Parties.

22.

NOTICES.

All notices or other communications that are required or permitted hereunder shall be in writing and delivered personally, sent by facsimile or email (and promptly confirmed by personal delivery or overnight courier), or sent by internationally-recognized overnight courier addressed as follows:

If to Collaborator, to the address(es) set forth in the Collaborator Notice Block on the Information Sheet.

If to MSD, to:

MSD International GmbH

▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇

6005 Luzern

Switzerland

Attention: Director

Facsimile: ▇▇▇ ▇▇ ▇▇▇ ▇▇▇▇

MSD International Business GmbH

▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇

6005 Luzern

Switzerland

Attention: Director

Facsimile: ▇▇▇ ▇▇ ▇▇▇ ▇▇▇▇

With copies (which shall not constitute notice) to:

Merck Sharp & Dohme Corp.

▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇

PO Box 100

Whitehouse Station, NJ 08889-0100

Attention: Office of Secretary

Email: ▇▇▇▇▇▇.▇▇▇▇▇▇▇▇▇@▇▇▇▇▇.▇▇▇

Merck Sharp & Dohme Corp.

▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇

Mailstop UG4CD-16

North Wales, PA 19454-2505

Attention: Senior Vice President, Research Science

Merck Sharp & Dohme Corp.

▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇

Mailstop K-1-3045

Kenilworth, NJ 07033-1310

Attention: Assistant General Counsel, Corporate Transactions

23.

RELATIONSHIP OF THE PARTIES.

The relationship between the Parties is and shall be that of independent contractors, and does not and shall not constitute a partnership, joint venture, agency or fiduciary relationship. Neither Party shall have the authority to make any statements, representations or commitments of any kind, or bind the other Party, except with the other Party’s express prior written consent. All Persons employed by a Party will be the employees of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for the account and expense of such Party.

24.

COUNTERPARTS AND DUE EXECUTION.

This Agreement and any amendment may be executed in any number of counterparts (including by electronic transmission), each of which shall be deemed an original, but all of which together constitute one and the same instrument, notwithstanding any electronic transmission, storage or printing of this Agreement. When executed by the Parties, this Agreement shall constitute an original instrument, notwithstanding any electronic transmission, storage or printing of this Agreement. For clarity, signatures transmitted by PDF shall be treated as original signatures.

25.

CONSTRUCTION.

Except where the context otherwise requires, wherever used, the singular includes the plural and vice versa, the use of any gender will be applicable to all genders, and the word “or” is used in the inclusive sense (and/or). Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. The captions of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The term “including” as used herein shall be deemed to be followed by the phrase “without limitation” or like expression. The term “will” as used herein means shall. The terms “hereof”, “hereto”, “herein” and “hereunder” and words of similar import when used in this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement. References to “Article,” “Section”, “Exhibit” or “Schedule” are references to the numbered sections of this Agreement and the appendices attached to this Agreement, unless expressly stated otherwise. A reference to any statute, law, rule, regulation or directive will be construed as a reference to such statute, law, rule, regulation or directive as amended, extended, repealed and replaced or re-enacted from time to time. A definition of or reference to any agreement, instrument or document herein shall refers to such agreement, instrument or other document as it may be amended, supplemented or otherwise modified from time to time (subject to any restrictions on such amendments, supplements or modifications set forth herein). Any reference to “agree,” “consent,” “approve” or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging). Except where the context otherwise requires, references to this “Agreement” shall include the appendices and schedules attached to this Agreement. The language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction will be applied against either Party hereto.

[Remainder of page intentionally left blank. Signature page follows.]

IN WITNESS WHEREOF, the respective representatives of the Parties have executed this Agreement as of the Effective Date.

AUM Biosciences Pte. Ltd

By:	/s/ ▇▇▇▇▇▇ ▇▇▇▇▇

Name:	▇▇▇▇▇▇ ▇▇▇▇▇

Title	Chairman, CEO

MSD International GmbH

By:

Name

Title

MSD International Business GmbH

By:

Name

Title

IN WITNESS WHEREOF, the respective representatives of the Parties have executed this Agreement as of the Effective Date.

AUM Biosciences Pte. Ltd

By:

Name

Title

MSD International Gm

By:	/s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇

Name:	▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇

Title:	Director

MSD International Business GmbH

By:	/s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇

Name:	▇▇▇▇▇▇ ▇▇▇▇▇▇▇

Title:	Director

Exhibit A

PROTOCOL SUMMARY

A-1

Exhibit B

SUPPLY OF COMPOUND

B-1

EXHIBIT C

DATA PROTECTION TERMS

C-1

EXHIBIT D

PRE-APPROVED COUNTRIES FOR MSD COMPOUND STUDY

D-1

Schedule I:

DATA SHARING SCHEDULE

Sch. I-1

Schedule II:
SAMPLE TESTING SCHEDULE

Sch. II-1

Example of Phase I Oncology Analysis and Reporting Essential

Tables/Figures/Listings

(As Applicable and Agreed to by JDC)

Example of Phase II Oncology Analysis and Reporting Essential

Tables/Figures/Listings

(As Applicable and Agreed to by JDC)

Schedule III –

THIRD PARTIES PROVIDING MSD COMPOUND STUDY ACTIVITIES

Sch. III-1

Clinical Trial Collaboration and Supply Agreement by and among MSD International GmbH, MSD International Business GmbH, and Collaborator (as defined below)

Document Metadata

Document Metadata

Table of Contents